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Alterations in intracellular calcium (Ca2+) are thought to play an important role in skeletal 
muscle weakness associated with muscular dystrophy due to the activation of Ca2+-
regulated proteases (calpains).  It was hypothesized that impirments in Ca2+ regulation 
are exacerbated in dystrophic muscle and that calpain inhibition could attenuate the 
muscle weakness induced by fatiguing contractions.  Single muscle fibres from control 
and dystrophic mice lacking dystrophin (mdx) and utrophin plus dystrophin (Utr-/-/mdx) 
were used.  Fibres from Utr-/-/mdx mice had similar peak tetanic Ca2+ compared to control 
and mdx mice, however Utr-/-/mdx mice took longer to clear the released Ca2+.  All fibres 
showed similar time to fatigue but fewer mdx and Utr-/-/mdx fibres remained excitable 1hr 
after fatiguing contractions.  Exposure to a calpain inhibitor improved Ca2+ levels in 
dystrophic fibres (mdx; trend only in Utr-/-/mdx) after fatigue.  Together, these data 
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Chapter 1: Introduction 
Duchenne muscular dystrophy (DMD) is one of the most frequent and devastating 
types of muscular dystrophy affecting humans (6; 26).  One in 3500 boys are born with the 
disease and few cases have been reported in girls (111).  Although DMD has received 
considerable attention due to its rapid progression and the early death of patients (12), there 
still is no cure for the disease.  Despite appearing normal at birth, affected individuals are 
often diagnosed as early as 3 years of age, become wheelchair bound between 8 and 12 years 
of age, and do not extend their life beyond the age of 30 (6).  It is known that skeletal muscle 
of patients with DMD lacks dystrophin (79), an essential protein maintaining stability in the 
muscle membrane (48; 104).  Dystrophin is a member of the dystrophin-associated complex 
(DAC) which connects the cytoskeleton of muscle fibres to proteins in its membrane (see 
Figure 1) (6).  The absence of dystrophin from the DAC contributes to the inability of the 
complex to function properly (6).  The absence of dystrophin also affects intrinsic 
mechanisms responsible for muscle force production and function (149), and increases the 
muscle’s susceptibility to stretch-induced damage (169). 
 
Figure 1. Schematic illustration demonstrating the role of dystrophin in the muscle fibre 
membrane.  Healthy muscle membrane with dystrophin in place maintaining the dystrophin-
associated complex (DAC) together (left) and dystrophic muscle where the absence of dystrophin 
leads to instability of the DAC (right).  The DAC is composed of syntrophins (α-1 and β-1), 
neuronal nitric oxide synthase (nNOS), α- and β-dystroglycans, laminin, sarcoglycans (α, β, δ, 
and γ), caveolin-3 (Cav-3), and dystrobrevin.  Also shown are filamentous (F)-actin which binds 
dystrophin to the cytoskeleton, collagen and the transient receptor potential canonical 1 (TRPC1) 




One of the proposed mechanisms by which dystrophin deficiency affects force 
production is the impairment in excitation-contraction (E-C) coupling (6; 149).  The process 
of E-C coupling involves all cellular events that link muscle excitation to force production 
(see Figure 2) (31).  This process is initiated by activation from the motoneuron, resulting in 
depolarization of the muscle membrane and activation of calcium (Ca2+) release (12).  The 
released Ca2+ binds to troponin C which allows force to be produced (12).  Several studies 
have demonstrated that muscle fatigue occurs in response to a failure in some process of E-C 
coupling (8; 32; 156).  This impairment in E-C coupling, leading to a decrease in free
intracellular Ca2+ concentration ([Ca2+] i) and force during repeated tetanic contractions (i.e. 
prolonged muscle activity), is due to both metabolite accumulation and to the elevation in 
resting [Ca2+] i (35).  Possible underlying causes for the impairments in E-C coupling and 
force production include defects in depolarization, slower rate of membrane repolarization, 
failure to activate dihydropyridine receptors (DHPR), impaired communication between the 
voltage sensors (DHPRs) and the Ca2+ release channels, and reduced rate of Ca2+ uptake by 
the sarcoplasmic reticulum (SR) leading to higher resting [Ca2+] i between contractions (7).  
The prolonged effects of muscle fatigue (i.e. muscle weakness) which persist after metabolic 
recovery (> 1 hr after a fatigue bout) are thought to be due primarily to the increases in 
[Ca2+] i during the tetanic contractions (32).  The accumulation of [Ca
2+] i during repeated 
muscle contractions, which contributes to acute muscle weakness (33; 98; 151), may also be 





Figure 2 - Skeletal muscle excitation-contraction coupling.  Muscle activation results in 
depolarization of the plasma membrane and the transverse tubules (t-tubules), which carry 
the signal to the interior of the fibre.  The voltage sensing dihydropyridine receptor (DHPR) 
detects the change in membrane potential and transmits the signal to the calcium release 
channel or ryanodine receptor (RYR).  The process of E-C-coupling is known to be impaired 
in DMD (adapted from 31).  
 
Ca2+ homeostasis is impaired in dystrophic muscle (14; 82).  Resting [Ca2+] i h s been 
shown to be higher in single muscle fibres (SMF) from the mdx mice (dystrophic mouse 
model for DMD) compared to control mice, as well as in humans (148; 24; 39; 75).  Yet, 
others have reported no differences (61; 102; 126).  It was previously reported that 
depolarization-induced SR Ca2+ release is reduced in SMF from dx mice (169).  However, 
more recent data suggest that stimulation-induced Ca2+ release is reduced only in a subset of 
branched fibres and not in non-branched SMFs (76).  The chronic change in Ca2+ 
homeostasis may affect SR function (87; 145).  The increased resting Ca2+ levels can lead to 
saturation of the SR Ca2+ pump responsible for Ca2+ uptake (48).  The increase in free [Ca2+] i 
is augmented by repeated muscle contractions, with the accumulation of Ca2+ being greater in 
branched muscle fibres (76).  The decline in force output with repeated muscle contractions 
(i.e. fatigue) is associated with a decrease in peak tetanic [Ca2+] i secondary to impaired E-C 




in control and non-branched single fibres from mdx mice but is greater in branched single 
fibres, leading to further decreases in peak [Ca2+] i nd an accelerated rate of fatigue (76). 
It has been proposed that Ca2+- ctivated proteases (calpains) play a role in this 
prolonged disruption of E-C coupling (98; 152).  This is a feasible hypothesis supported by 
studies demonstrating the activation of calpains (calpain-3 and µ-calpain) by [Ca2+] i in the 
physiological range of muscle contractions (0.5 – 3.0µM) (26; 117; 118).  Calpains are on-
lysosomal Ca2+-activated proteases that, when activated, participate in the breakdown of 
muscle constituents.  Although the role of calpains is still unclear, it has been suggested that 
they participate in the process of remodeling the cytoskeletal structure and have close 
interaction with the plasma membrane (62).  Calpains are necessary during the development 
of muscle fibres, due to the extensive remodeling required, but only calpain-3 is essential for 
adult muscle, since its absence is related to the development of limb-girdle muscular 
dystrophy type 2A (62, 116). 
The two calpains most commonly found in muscle are calpain-3 (also referred to 
p94), which is bound near the triad junction at the N2A line in titin, and µ-calpain (also 
called calpain-1), localized in the I-band region (91; 120, 170).  Calpain-3 is autolyzed in the 
presence of Ca2+ by removal of a propeptide that covers its catalytic site, thus producing three 
different protein products with molecular weights of 60-, 58-, and 55kDa (63).  The proc ss 
by which µ-calpain is autolyzed, in a Ca2+ dependent manner, involves the cleavage of the 
NH2-terminal domain which reduces its size from 80kDa to 78kDa and 76kDa (67).  Due to 
the increased muscle breakdown and protein turnover in the mdx mice, several groups have 
investigated the level of calpain activation in this mouse model (62; 156; 141).  It has been 
reported that the mdx mice have an average 1.5-fold increase in calpain activation compared 




modification (139).  This enhanced activation has been reported in muscles undergoi g 
damage, with the calpain levels returning to normal when the muscle is regene ating (139). 
Studies investigating underlying mechanisms (62; 76; 169) and potential treatments 
(48; 134) for DMD have largely been done in mdx mice.  However, the only muscle in the 
mdx mice demonstrating similar disease progression to DMD patients, with progressive 
degeneration and detectable muscle weakness, is the diaphragm (143).  This is because 
utrophin, a protein with a similar role to dystrophin in muscle, is upregulated in these animals 
therefore compensating for the lack of dystrophin in most muscles (70; 149).  Also, it has 
been shown that satellite cell function in the mdx mouse is higher, thus enhancing muscle 
regenerative capacity and contributing to the milder disease severity (131).  Consequently, a 
double mutant model (animals lacking both dystrophin and utrophin) is thought to be a more 
suitable model for DMD (37; 70).  In a study by Capote and colleagues (29), [Ca2+] i
  was 
assessed in SMFs from control, mdx and the utrophin knockout (Utr-/-)/mdx double mutant 
mice  (Utr-/-/mdx).  The study demonstrated that peak Ca2+ release was not different between 
mdx and Utr-/-/mdx mice, although Ca2+ release was suppressed by 28-32% in fibres from 
both these models compared to control mice (29).  These authors proposed that the mdx 
phenotype is not significantly ameliorated by utrophin overexpression (29).  In response to 
repeated tetanic contractions, muscle fibres from the Utr-/-/mdx mice had a greater decay in 
Ca2+ transients (i.e. greater fatigue) compared to the mdx and control mice (29).  However, it 
is not fully known whether the prolonged reduction in muscle force akin to muscle weakness 
is exacerbated in the muscle fibres from the Utr-/-/mdx mice. 
Muscle fibre recovery after fatigue has been described to be dependent upon the 
frequency at which the muscle is stimulated and the levels of [Ca2+] i.  As first presented by 
Edwards et al. in 1977 (55), muscles are not able to recover force production when stimulated 




recovered when the muscle is stimulated at high frequency after fatigue (approximately 20 
minutes for full recovery).  Thus, this slow component of recovery from fatigue is not caused 
by depletion of high energy phosphate (55) or damage to myofibrillar proteins.  It was further 
shown that the slow recovery from fatigue was not caused by decreased levels of m tabolites, 
but rather due to a reduction in free [Ca2+] i (159).  Chin and Allen (33) showed that 
prolonged reductions in force following fatigue were not related to decreases in Ca2+
sensitivity or decreases in force-generating capacity, but instead occurred due to a reduction 
in Ca2+ release.  This impairment in Ca2+ release, which adds to the long-lasting recovery 
from fatigue, occurs due to increases in [Ca2+] i during fatiguing stimuli affecting E-C 
coupling (33; 98).  This failure in E-C coupling can be caused by either exposing muscle 
fibres to high Ca2+ concentrations (1mM for 10 seconds) or by prolonged exposure (60 
seconds) to lower concentrations (2.5µM) (98). 
It is hypothesized that E-C coupling disruption is greater in muscles that lack both 
dystrophin and utrophin leading to prolonged decrease in force production following bouts of 
contractions.  Therefore, the purpose of the present study was to investigate the effects of 
repeated contractions leading to muscle fatigue on [Ca2+] i and E-C coupling failure.  The 
prolonged muscle weakness after fatigue in Utr-/-/mdx compared to mdx and control mice, as 
well as the role of calpains in this prolonged decrease in E-C-coupling was evaluated. 
 
Specific Aim 1: to determine if E-C coupling failure during fatigue was more 
pronounced in SMFs from Utr-/-/mdx compared to mdx and control mice. 
Hypothesis 1: E-C coupling disruption will be greater in SMFs from Utr-/-/mdx 





Specific Aim 2: to determine if prolonged muscle weakness due to E-C coupling 
disruption was exaggerated in SMFs from Utr-/-/mdx compared to mdx and control mice. 
Hypothesis 2: prolonged muscle weakness will be greater in SMFs from Utr-/-/mdx 
compared to mdx and control mice. 
 
Specific Aim 3: to determine whether prolonged muscle weakness was due to calpain 
activation in mdx and Utr-/-/mdx mice. 
Hypothesis 3: calpain inhibition will attenuate the prolonged muscle weakness after 




















Chapter 2: Methods 
2.1 - Animals 
All protocols for animal handling have been approved by the Institutional Animal 
Care and Use Committee (IACUC).  An IACUC approved protocol for breeding these mice 
was obtained by Dr. Eva Chin.  All groups were kept in the same room (regular ambient 
conditions – 20.9% of oxygen and 22±1
o
C) and had the same access to food and water, 
bedding, and light cycle (12h light/12h dark). 
Three controls (C57BL/10ScSn) were obtained from Jackson laboratories.  Three 
Utr+/-/mdx breeders (two females and one male) were obtained in collaboration with Dr. 
Diego Fraidenraich from University of Medicine and Dentistry, New Jersey, and in 
collaboration with Dr. Robert Grange from Virginia Tech University.  Colonies of Utr+/-/mdx 
mice were bred at the University of Maryland Central Animal Research Facility (CARF) 
according to previously published breeding schemes (50).  Once females appeared r gnant, 
they were removed from the male and housed separately until after pups were born and 
weaned.  Offspring were weaned at day 21 and sorted by gender and then used for 
assessment of SMF contractile function at approximately two months of age.  It was expected 
that 25% of the pups born would be Utr+/+/mdx (or mdx) and 25% would be Utr-/-/mdx, while 
the other 50% would be Utr+/-/mdx.  However, out of 3 generations and a total of 30 animals 
only 2 animals were characterized as Utr-/-/mdx.  This is consistent with the findings of others 
(R. Grange, personal communication) and indicates some in ut ro loss of the Utr-/-/mdx mice.  
The criteria for distinguishing mdx and Utr-/-/mdx included body weight and spine curvature 
of animals (see Figure 3).  It is known that the Utr-/-/mdx mice demonstrate kyphotic posture 
and have lower body weight (approximately 10 grams less) compared to mdxand controls 








Figure 3. Utr-/-/mdx were distinguished from mdx based on body weight and spine curvature.  
Picture on the top (A) demonstrates differences in size between mdx and Utr-/-/mdx, while bottom 
picture (B) shows the kyphosis present in the Utr-/-/mdx compared to mdx mouse (red arrows).  
 
 
2.2 Study Design 
The present study had 3 groups: a control (CON) group (n=3), a Utr+/-/mdx or 
Utr+/+/mdx (these animals will be referred as mdx throughout the document since we cannot 
currently distinguish between these genotypes) (n=9), and a Utr-/-/mdx group (n=2). Muscle 
fibres from dystrophic animals demonstrate differences in fibre shape (somnor al while 
some are called “branched”) as they age (29; 104; 76).  However, the present study only 
investigated fibres that had normal shape. 
 
 




Animals were euthanized by cervical dislocation after exposure to carb n dioxide 
(CO2) in a closed chamber.  The feet were removed for dissection of SMFs from the flexor 
digitorum brevis (FDB) muscle.  Furthermore, the protocol for isolating SMF from the FDB 
muscle has been previously tested (108).  Muscle fibres were acquired after 4h digestion in a 
collagenase/minimal essential medium (MEM) solution.  Fibres were incubated during 
digestion at 37oC in order to maintain their normal physiological characteristics.  
Subsequently, fibres were incubated and preserved in MEM solution with 10% fetal bovine 
serum (FBS) at 37oC.  The protocol has been tested in a previous study (108). 
 
2.3.1 Intracellular Ca2+ measurements.  One day after dissection (day 1) fibres were 
loaded with Fura-2AM for 15 minutes in order to measure [Ca2+] i.  Fifteen minutes of 
incubation with Fura-2AM allows enough time for fusion of the fluorescent indicator into the 
muscle fibre myoplasm.  The presence of the AM portion in the Fura-2 compound gives the 
advantage of loading without injecting the dye into the fibre.  The addition of the AM portion 
allows the indicator to enter the myoplasm, where esterases remove the AM group, which 
then traps the indicator in the cytoplasm (153).  Loaded fibres were then placed in a 
stimulation chamber containing parallel electrodes on top of a Nikon TiU microscope.  
Intracellular Ca2+ levels were assessed using Fura-fluorescence with an IonOptix 
Hyperswitch system for dual excitation, single emission dyes with filters sets for Fura-2.  The 
Ca2+ indicator Fura-2 has peak fluorescence at 510 nm when excited at 380nm in the 
unbound state but shifts to peak fluorescence at 510nm when excited at 340nm when bound 
to Ca2+.   The ratio of emission at 510nm when excited at 340 and 380nm (i.e. Ratio = 
340nm/380nm) represents the intracellular free [Ca2+] i.  The IonOptix hardware includes the 
MyoCam-S which allows for control over the spatial field of video acquisition and 




shown on the video window of the computer screen, effectively allowing one to obtain 
fluorescence signals from one fibre at a time.  Fluorescence from other nearby muscle fibres 
do not influence the Fura-2 ratio of the fibre in the image acquisition field.
 
2.3.2 Single muscle fibre stimulation protocol.  The muscle fibres used in the present 
study were selected based on having a normal shape (non-branched) and responding to 15Hz 
stimuli.  This criteria was used to avoid bias when selecting fibres for data collection.  Single 
fibre [Ca2+] i was assessed in muscle fibres using 350msec tetani at 10, 30, 50, 70, 100, 120, 
and 150Hz stimulation frequencies.  One minute of rest was allowed between frequencies, 
and then fibres rested for 10 minutes before assessing the 7 frequencies again.  Ri ht after the 
first set of stimuli, fibres were either perfused with drug or vehicle for testing the acute 
effects of either exposure.  Then, fibres rested for 10 more minutes before inducing fatigue.  
Fibres were then assessed again 1 hour after fatigue at the same 7 stimulation frequencies to 
evaluate the prolonged decrease in muscle function.  Muscle fibres were continuously 
perfused with a stimulating tyrode solution throughout data collection (units in mM - NaCl, 
121.0; KCl, 5.0; CaCl2, 1.8; MgCl2, 0.5; NaH2PO4, 0.4; NaHCO3, 24.0; and glucose, 5.5) 
(34).  This solution was bubbled with 95% O2/5% CO2 to give a pH of 7.3 (34).  To assist in 
the survival of SMFs during perfusion, 0.2 % FBS was added to each solution (34).  After the 
first set of stimuli, fibres were continually perfused with stimulating yrode with the addition 
of either drug or vehicle throughout the entire protocol. 
 
2.3.3 Assessment of muscle fatigue and prolonged muscle weakness.  Fatigue was 
induced by intermittent 100Hz tetani (350msec duration) starting at 1 contraction every 4 




every 2 seconds for 2 minutes, and then 1 contraction every second for 2 minutes (32).  Time 
to 50% of initial Fura-2 ratio was used as index of fatigue.  One hour following fatigue, 
single fibre [Ca2+] i were re-assessed in the same fibre using the same stimulation protocol 
(10, 30, 50, 70, 100, 120, and 150Hz) to determine the prolonged decrease in E-C coupling as 
an index of muscle weakness (35). 
 
2.4 Determining the role of Calpains in Muscle Weakness 
In order to evaluate the role of calpains in the prolonged decrease in E-C coupling, 
muscle fibres were continuously perfused with a calpain inhibitor after the first set of 
stimulation frequencies and throughout the entire protocol.  The 60 min recovery from 
fatigue was compared between fibres exposed to the calpain inhibitor and those exposed to a 
vehicle solution (stimulating tyrode with 100% ethanol).  In this study calpain w s inhibited 
by a pan-protease inhibitor (ALLN, EMD Biosciences) which is most potent for the Ca2+ 
activated proteases µ-calpain (inhibitor constant (Ki) 190nM) and calpain-2 (Ki 220nM), 
compared to other proteases (Cysteine Proteases and Proteasome Ki 6uM), although it also 
potently inhibits Cathepsin B (Ki 150nM) and Cathepsin L (Ki 500pM).  The limited choice 
of commercially available calpain inhibitors in addition to their lack of specificity was the 
main reason for selecting the pan-protease inhibitor ALLN. 
 
2.5 Statistical Analysis 
SPSS software (version 18.0; IBM Somers, NY) was used to calculate differences 
between and within groups in Fura-2 ratio (resting, peak, and 75% of Fura-2 peak clearance), 
time to fatigue, increase in resting Fura-2 ratio during fatigue, and pre- vs. post fatigue Fura-2 




comparisons with the Tukey test for post-hoc analyses.  For changes in fluorescence pre- vs. 
post fatigue, a paired t-test was performed.  The statistical significance was defined at 










































Chapter 3: Results 
Animals and single muscle fibres 
 The experiments were carried out in 2 month old mice.  The body weight of Utr-/-
/mdx was lower than mdx (p<0.05) and CON (p<0.05) mice.  A total of 13 SMF from CON 
were analyzed while 46 and 14 fibres from mdx and Utr-/-/mdx were analyzed, respectively.  
All 13 fibres analyzed from CON were used for the entire protocol.  In the mdx group, 24 out 
of 46 fibres were exposed to the full protocol, while 7 out of 14 fibres were assessed in the 
Utr-/-/mdx group.  The number of total fibres included those that responded to the 15Hz 
stimulus and were used for the entire protocol or only part of it.  The number of fibres treated 
with either ALLN or Vehicle represents all fibres that completed the entire protocol and 
which did not fail to respond to a stimulus prior to the last set of stimulation frequencies.  
Table 1 shows the characteristics of animals and the number of fibres used per group. 
Table 1 – Number of animals and single muscle fibres assessed per group 
  
n 







CON 3 26.15  ± 0.47g 13 7 6 
mdx 9 27.85 ± 2.73g 46 9 15 
Utr -/-/mdx  2 14.75* ± 3.04g 14 4 3 
  
The number of fibres completing the full protocol was lower than the starting number 
of fibres.  Fibres where the Ca2+ plateau did not maintain a peak or that would not respond to 
stimuli were not assessed for the rest of the protocol.  Therefore, any fibre failing to maintain 
peak at any frequency prior to fatigue was not exposed to the entire protocol.  Table 2 shows 
the number of fibres either failing or not responding to stimulus during the protocol in each 




fibres in each group, while the denominator in the second and fourth columns corresponds to 
the total number of fibres exposed to the full protocol. 
 
 
Table 2 - Number of fibres failing or not responding to stimulus before or after fatigue. 
 Fibres failing to maintain peak  Fibres not responding to stimulus  
 Before fatigue  After fatigue  Before fatigue  After fatigue  
CON 0/13 1/13 0/13 2/13 
mdx 18/46 6/24 4/46 4/24 
Utr -/-/mdx  7/14 4/7 0/14 2/7 
 
 
 The diameter and length of SMFs are shown in Figures 4 and 5.  Fibre diameter from 
the Utr-/-/mdx mice was smaller compared to the fibres in the two other groups (p<0.05).  
There were no differences in fibre length between groups (CON vs. mdx, p=0.69; CON vs. 
Utr-/-/mdx, p=0.92; mdx vs. Utr-/-/mdx, p=0.38). 
 
Figure 4.  Single muscle fibres from Utr-/-/mdx mice had a reduced diameter compared to CON 
and mdx mice.  Average fibre diameter was calculated for all fibres from each group (n= CON: 



































Figure 5.  Fibre length was similar between groups.  Average fibre length was calculated based on 
all fibres from each group (n= CON: 13; mdx: 46; Utr-/-/mdx: 14).  Data shown are mean ± SE. 
 
Ca2+ handling 
 Resting Fura-2 ratio, representing resting intracellular Ca2+, was higher in mdx fibres 
compared to CON (p<0.05), but not in comparison to Utr-/-/mdx mice (p=0.44) (Figure 6).  
There were no differences in resting Fura-2 ratio between CON and Utr-/-/mdx (p=0.32) 
(Figure 6).  Peak Fura-2 ratio was not different between groups for all stimulation 
frequencies, which demonstrate that fibres from all groups had similar starting levels of 
tetanic intracellular Ca2+ (p values are listed in appendix).  In order to assess Ca2+ cle rance 
by parvalbumin (PV) binding and the SR Ca2+ ATPase, the time required to reduce the Fura-
2 level back to 25% of the peak level (i.e. 75% peak Fura-2 clearance) was determined (see 
Figure 7).  There were no differences in 75% peak Fura-2 clearance between 50Hz and 
120Hz within groups (CON, p=0.38; mdx, p=0.32; Utr-/-/mdx, p=0.19) (Figure 8).  These two 
frequencies were selected because they represent examples of low and high stimulation 
frequencies.  Figure 8 also shows that the time for 75% of Fura-2 peak clearance t 50Hz was 




Similar results were reported at 120Hz, in which Utr-/-/mdx fibres required a longer time to 
clear 75% of total released Fura-2 peak compared to controls (Figure 8). 
Figure 6.  Resting Fura-2 ratio was higher in mdx compared to CON.  Resting Fura-2 ratio was 
calculated from all fibres in each group (n= CON: 13; mdx: 46; Utr-/-/mdx: 14).  Data shown are 
mean ± SE.  * p<0.05. 
 
 
Figure 7. Raw data figure demonstrating the Fura-2 ratio response to a stimulation frequency.  
Different parts of the Fura-2 tracing shown: resting Fura-2 ratio, time point when single muscle 
fibre is depolarized, peak Fura-2 ratio, and the time point at which 75% of Fura-2 peak is 
removed.  The first step in determining 75% of Fura-2 peak clearance involves the calculation of 
the difference between Fura-2 peak (i.e. 1.2) and resting Fura-2 ratio (i.e. 0.3).  Then, 25% of the 
difference is calculated (i.e. (1.2-0.3)*.25=.225).  This number is added to the resting Fura-2 ratio 
(i.e. 0.3+.225=0.525).  Then, the time point corresponding to this value when peak Fura-2 is 
decreasing is recorded (i.e. 1.238 sec).  Lastly, the difference between time of 25% of Fura-2 
peak and time of last part of the Fura-2 peak is calculated (i.e. 1.238-1.158 = .80sec).  This last 



















Figure 8.  Time taken for 75% of Fura-2 peak clearance at 50 nd 120Hz.  Time taken for 75% of 
Fura-2 peak clearance was longer in Utr-/-/mdx compared to CON at 50Hz and 120Hz (trend seen 
between mdx and Utr-/-/mdx at 50Hz - p<0.10).  Time taken for 75% of Fura-2 peak clearance 
was calculated for all fibres demonstrating normal responses to tetani at he first set of stimulation 
frequencies (n: CON=13; mdx=32; Utr--/-/mdx=8).  Data shown are mean ± SE. * p<0.05; # 
p<0.10. 
 
Resistance to fatigue 
In the present study, fatigue was determined as 50% decrease in peak Fura-2 ratio 
during repeated muscle contractions (raw data figure demonstrating fatiguing contractions is 
shown in Figure 9).  As shown in Figure 10, there were no differences between groups in 
time to fatigue (CON vs. mdx, p=0.73; CON vs. Utr-/-/mdx, p=0.61; mdx vs. Utr-/-/mdx, 
p=0.23).  Also, there were no differences in the magnitude of the increase in resting Fura-2 
ratio during fatigue (see Figure 11; CON vs. mdx, p=0.98; CON vs. Utr-/-/mdx, p=0.75; mdx 
vs. Utr-/-/mdx, p=0.79).  However, an interesting finding in the present study was that 6 out of 
the 7 (~86%) fibres in the Utr-/-/mdx stimulated to fatigue were either unable to respond to 
stimuli after fatigue or demonstrated failing peaks.  Moreover, the other two groups also had 






















percentage of fibres failing (due to either condition noted above) was lower cmpared to Utr-
/-/mdx fibres (CON=3/10 (~30%); mdx=10/24 (~42%)). 
 
Figure 9.  Raw data figure showing an example of fatiguing contractions.  Time to fatigue was 
determined as 50% decrease in peak Fura-2 ratio from first Fura-2 peak (each individual line 
upwards is a single Fura-2 peak).  Note the increase in restig Fura-2 ratio during contractions 












Figure 10. There were no differences in time to fatigue between groups.  Time to fatigue was 
defined as time taken to reach 50% of initial peak during fati ue (n= CON: 13; mdx: 24; Utr-/-























Figure 11. Increase in resting Fura-2 ratio during fatigue was not different between groups.  
Increase in resting was calculated as the difference between resting Fura-2 ratio for the tetanus 
demonstrating 50% of initial peak and the starting resting Fura-2 ratio (n= CON: 13; mdx: 24; 
Utr-/-/mdx: 7).  Data shown are mean ± SE. 
 
Effect of drug treatment on fatigue resistance 
 When comparing time to fatigue for each treatment condition (Vehicle and ALLN), 
there were no between-group differences (CON vs. mdx vs. Utr-/-/mdx) in time to fatigue in 
the sub-set of SMFs (Figure 12).  Also, there were no differences in the increase in resting 
Fura-2 ratio during fatigue in vehicle- or ALLN-treated fibres (Figure 13).  No within-group 
differences between Vehicle vs. ALLN treatment were reported for time to fatigue or 



















Figure 12.  There were no differences within or between groups in time to fatigue between fibres 
exposed to Vehicle compared to ALLN.  Time to fatigue was defined as time taken to reach 50% 
of initial peak during fatigue (n= CON: 7 Vehicle – 6 ALLN; mdx: 9 Vehicle - 15 ALLN; Utr-/-

















Figure 13.  There were no within or between group differences in increase in resting Fura-2 ratio 
during fatigue for fibres exposed to Vehicle or ALLN.  Increase in resting was calculated as the 
difference between resting Fura-2 ratio from peak demonstrating 50% of initial peak and starting 
resting Fura-2 ratio (n= CON: 7 Vehicle – 6 ALLN; mdx: 9 Vehicle - 15 ALLN; Utr-/-/mdx: 4 







Effects of calpain inhibitor in single muscle fibre function 
 As shown in Figures 13 (CON) and 14 (Utr-/-/mdx), SMFs treated with vehicle had 
similar peak Fura-2 ratio for all stimulation frequencies from pre- to post-fatigue (refer to 
appendix for p values).  This suggests that there was no prolonged impairment in E-C 
coupling in these fibres (Figures 13 and 14).  There were also no peak Fura-2 ratio 
differences after fatigue with ALLN in these two groups (Figures 16 and 17).  However, 
SMFs from mdx mice treated with vehicle had lower peak at 10 (p<0.05), 120 (p<0.05), and 
150Hz (p<0.05) after fatigue, while there was a trend for other frequencies (30Hz: p=0.055; 
50Hz: p=0.068; 70Hz: p=0.063; 100Hz: p=0.056) (Figure 15), a marker of prolonged 
impairment in E-C coupling induced by the fatiguing tetani.  In this group, SMFs treated with 
ALLN demonstrated no reduction in peak Fura-2 ratio from pre- to post-fatigue 
measurements indicating that ALLN suppressed the prolonged impairment in E-C coupling 



















Figure 14.  Pre- vs. post-fatigue peak Fura-2 ratio in Vehicl treated single muscle fibres from 
CON mice.  Peak Fura-2 ratios are shown across the range of stimulation frequencies assessed 





























Figure 15.  Pre- vs. post-fatigue peak Fura-2 ratio in Vehicl treated single muscle fibres from 
Utr-/-/mdx mice.  Peak Fura-2 ratios are shown across the range of stimulation frequencies 






Figure 16.  Pre- vs. post-fatigue peak Fura-2 ratio in Vehicl treated single muscle fibres from 
mdx mice.  Peak Fura-2 ratios are shown across the range of stimulation frequencies assessed pre- 


















































Figure 17.  Pre- vs. post-fatigue peak Fura-2 ratio in ALLN treated single muscle fibres from 
CON mice.  Peak Fura-2 ratios are shown across the range of stimulation frequencies assessed 
























Figure 18.  Pre- vs. post-fatigue peak Fura-2 ratio in ALLN treated single muscle fibres from Utr-
/-/mdx mice.  Peak Fura-2 ratios are shown across the range of stimulation frequencies assessed 























Figure 19.  Pre- vs. post-fatigue peak Fura-2 ratio in ALLN treated single muscle fibres from dx 
mice.  Peak Fura-2 ratios are shown across the range of stimulation frequencies assessed pre- and 
































Chapter 4: Discussion 
Although the primary cause of DMD has been related to the lack of the protein dystrophin 
(79), many of the underlying mechanisms contributing to the disease severity have not be n 
identified.  The weakening of the muscle membrane is considered to be one of the 
mechanisms contributing to the disease severity (18).  It is known that dystrophic muscle has 
greater susceptibility to damage during eccentric contractions compared to normal muscle 
(169).  A second mechanism that is thought to contribute to the disease severity is r lated to 
signaling modifications within dystrophic muscle.  Studies have shown that muscles la king 
dystrophin have increased oxidative stress, decreased antioxidant capacity, and poor 
intracellular Ca2+ handling (66; 128; 80). 
 The present study was designed to compare intracellular Ca2+ egulation, fatigue 
resistance, and the prolonged muscle weakness in two animal models for DMD.  Also, we 
evaluated the role of calpain inhibition in prolonged muscle weakness in dystrophic muscle.  
Our results agree with previous findings by demonstrating impairments in intracellular Ca2+ 
handling in dystrophic muscle (104; 166; 75).  It was observed that dystrophic SMFs have 
higher resting [Ca2+] i and slower rate of Ca
2+ clearance.  Yet, we did not observe differences 
in peak tetanic Ca2+ between dystrophic mouse models and controls as previously reported 
(80; 165; 166).  Present findings suggest that SMFs from dystrophic animals have imilar 
resistance to fatigue as controls, but are less likely to respond to electrical activation after 
being challenged with fatiguing contractions.  A novel finding from this investigation is 
related to the role of calpains in the prolonged muscle weakness in dystrophic muscle.  
Dystrophin deficient SMFs treated with calpain inhibitor were able to maintain Ca2+ peaks 
after fatiguing contractions, whereas fibres treated with vehicle showed prolonged reductions 





Table 3 – Summary of differences between the two dystrophic mouse models compared to 
controls. 
 
mdx Utr -/-/mdx  
Fibre length Similar to CON Similar to CON 
Fibre diameter Similar to CON ↓↓ 
Resistance to fatigue Similar to CON Similar to CON 
Increase in resting Ca2+ 
during fatigue Similar to CON Similar to CON 
Resting Ca2+ ↑↑ ↑ 
Ca2+ clearance Similar to CON ↓↓↓ 
Ability to respond to 
stimulus after fatigue ↓ ↓↓↓ 
Ability to maintain Ca 2+ 
peaks after fatigue ↓↓ ↓↓↓ 
 
 
Morphology of muscle fibres 
Capote and colleagues (29) assessed the morphological characteristics of SMFs from 
Utr-/-/mdx mice compared to CON and mdx, and found that Utr-/-/mdx SMFs are thinner and 
shorter compared to the fibres from other mice.  Results from the present study also reported 
that the diameter of SMFs from Utr-/-/mdx is smaller compared to CON and mdx.  However, 
we did not observe differences in fibre length between groups.  Differences in the numb r of 
analyzed fibres could be one of the factors contributing to the discrepancies in findings.  
Therefore, a more thorough evaluation with an increased number of fibres is needed to 
confirm if Utr-/-/mdx SMFs have reduced diameter and shorter in length. 
 
Resistance to fatigue in dystrophic muscle 
 The present results show that resistance to fatigue is similar between dystrophic and 
normal SMFs.  It has been previously reported that the EDL muscle from the dx mice have 




fatigue resistance at 20°C were reported in the same study between mdx a d age-matched 
controls during the first 2 minutes of fatiguing contractions, but at the end of the fatigue 
protocol (5 min.) the EDL from mdx mice demonstrated a greater fatigue (162).  Contrary to 
these findings, Hayes and Williams reported that the EDL from mdx mice shows greater 
fatigue than controls during the first 2 minutes of repeated contractions at 20°C, while no 
differences were present at the end of 5 minutes (74).  Other studies have demonstrated that 
the EDL muscle of mdx mice is less fatigable compared to controls at more physiological 
temperatures (35°C), while no differences are seen under lower temperatures (20°C) (1; 9; 
54).  Our results agree with the studies demonstrating no changes in fatigue resistance 
between the EDL muscle from dx and control mice at ambient (20-22oC) temperature. 
Differences in findings can be attributed to several factors.  First, most studies have 
evaluated whole muscle resistance to fatigue, while we evaluated individual SMFs.  Whole 
muscle is a mixed population of fibres. The EDL is a mixed fast-twitch muscle with higher 
percentage of type IIb fibres (88%), whereas the FDB is 75% type IIX/D and 25% of a mix 
of type I and IIa fibres (13; 5).  It is not known if the fibres in the present study were either 
type I, type IIa, type IIx, or type IIb.  Secondly, different results could be related to the type 
of muscle preparation used.   In most studies evaluating fatigue resistance, mus les are set at 
length for optimal force production, and then exposed to fatiguing contractions.  This 
produces a stretch component to some sarcomeres undergoing fatigue.  In the protocol used 
in the present study, SMFs were not stretched and during stimulation undergo unloaded 
shortening.  Although the protocol used in whole muscle studies does not involve significant 
lengthening contractions, the stretching of some sarcomeres could have influenced the 
findings.  Dystrophic muscle is known to demonstrate a much greater drop in force during 




unloaded SMFs used in the present study, there would be no sarcomeres being lengthened 
and therefore they are less susceptible to a stretch-induced damage. 
 One of the limitations in using SMF for assessing fatigue is the variability between 
fibres.  As shown by Lannergren and Westerblad (101), the time to reach fatigue in SMFs 
from a normal FDB ranges greatly (between 2 to 24 minutes).  This contributes to variability 
within groups, and could limit our findings regarding differences in fatigue resistance 
between mouse strains.  Resistance to fatigue is related to fibre diameter nd l ngth (101), 
and we attempted to use fibres of similar size in the present study to account for such 
variability.  Yet, as shown in Figure 5, we reported large variability in the tim  to fatigue 
within groups (note standard error bars).  Another potential limitation in the assessment of 
muscle fatigue in the present study is related to the criteria used to determin  fatigue.  Chin 
and Allen (33) reported that time taken to reach 30% of initial force (their crite ia for muscle 
fatigue) corresponds to a 50% decrease in tetanic Ca2+.  Thus, 50% decrease in Fura-2 peak 
(which would correspond to a 50% decrease in tetanic Ca2+) w s the rationale used to 
determine fatigue in the present study.  However, it is not known if the same criteria an be 
used in dystrophic muscle, since force decrease occurs faster in dystrophic muscle odels 
while the rate of change in Ca2+ might not follow the same pattern. 
 
Ca2+ handling in dystrophic vs. normal muscle - Resting Ca2+ 
It has previously been reported that muscle samples from dystrophic patients have 
higher Ca2+ content compared to controls (39; 24) and patients with other myopathies (24).  
This was further supported by studies demonstrating higher resting [Ca2+] i in cultured cells 
from DMD patients and SMFs from dystrophic mouse models (113; 14; 82).  Results from 
the present study agree with previous findings by showing an increased resting [Ca2+] i in 




resting [Ca2+] i between mdx and controls (36; 75; 104; 61; 102; 126).  One of the reasons for 
such discrepancies is related to the dye used for [Ca2+] i measurements.  Fura-2AM is known 
to generate variability in [Ca2+] i measurements, if time of loading and time interval between 
loading and data collection are not consistent (163).  Other reasons for discrepancies in 
findings are related to the age of mice (36) and the muscles assessed (80). 
Potential mechanisms that could explain the higher resting Ca2+ in dystrophic muscle 
are related to leakage of Ca2+ from the SR (145; 48; 22) and greater influx of Ca2+ through 
the plasma membrane during muscle contractions (3; 168; 169).  Takagi and colleagues (145) 
evaluated Ca2+ control by the SR in dystrophic muscles, and results showed an increased 
leakiness of the SR to Ca2+.  Further, it was shown that dystrophic muscles have 
hypernitrosylated RyR, which consequently depletes one of the channel binding stabilizing 
proteins (calstabin).  Therefore, this mechanism also contributes to Ca2+ leak through RyR.  
Moreover, this process worsens as dystrophic muscles age (22).  The movement of large 
proteins, such as albumin and CK, through the plasma membrane of muscles lacking 
dystrophin suggested the potential role of membrane tears in allowing the transit of many 
different molecules through the plasma membrane (109).  Therefore, scientists believe that 
Ca2+ influx was increased in dystrophic muscle due to the presence of such membrane tears 
(109).  However, Yeung and colleagues (169) demonstrated that Ca2+ influx happens through 
Ca2+ channels and not membrane tears.  Furthermore, it was shown that these channels 
belong to the TRPC family, and that inhibition of their activity almost completely suppressed 
the entry of Ca2+ in dystrophic fibres (150). 
To our knowledge there are no studies investigating resting Ca2+ levels in SMFs from 
Utr-/-/mdx mice compared to mdx and controls.  Based on the more pronounced disease 




demonstrate either similar resting [Ca2+] i than mdx fibres, or higher values.  However, resting 
Fura-2 ratio was similar between Utr-/-/mdx and the other two groups (mdx and CON). 
 
Ca2+ handling in dystrophic vs. normal muscle - Peak Ca2+ 
 Studies evaluating differences in Ca2+ peak between mdx and control fibres have 
shown inconsistent results (36; 80; 104; 165; 166).  While some studies have reported no 
differences between mdx and control mice (147; 148; 75), others have shown lower Ca2+ 
release in dystrophic muscle (80; 104; 165; 166).  The present study reported no differences 
in Ca2+ peak at several different stimulation frequencies between mdx, Utr-/-/mdx, and con 
mice.  Disagreements in findings could be related to type of fluorescent dye used (high 
affinity vs. low affinity).  Studies using high affinity fluorescent dyes did not report any 
differences in peak Ca2+ (75; 36; 147; 148), whereas studies using low affinity Ca2+ dyes 
showed lower Ca2+ release in mdx fibres (80; 165; 166).   According to Hollingworth (80), 
high affinity slowly responding Ca2+ dyes, such as Fura-2 and Indo-1, do not allow one to 
accurately distinguish changes in Ca2+ mplitude and time course (80),   Another reason for 
disagreements in findings can be related to the method for loading the dye (microinjection vs. 
AM-loading).  Fluorescent dyes that are loaded into fibres by the presence of the AM portion 
might yield less reliable Ca2+ measurements than dyes loaded by microinjection (80).   
Lastly, as suggested by Hollingworth et al. (80), the method for SMF isolation might 
influence in the assessment of Ca2+ levels (enzyme-dissociated vs. manually dissected). 
 The dystrophic groups in the present study had more fibres failing to maintain peak 
Ca2+ compared to controls (Utr-/-/mdx: 50%; mdx: 40%; CON: none).  As shown by Capote et 
al. (29) SMFs from mdx and Utr-/-/mdx can be separated in two groups: those with similar 




and amplitude as controls.  Fibres with similar AP as controls released at least 30% less Ca2+ 
when stimulated compared to controls, whereas fibres with longer AP showed less than 60% 
of peak Ca2+ from controls (29).  The authors also observed that SMFs with longer AP had 
abrupt limitation in Ca2+ release at 100Hz, whereas this was almost unnoticed at 50Hz (29).  
This suggests that some dystrophic muscle fibres have impaired Ca2+ rele se at higher 
frequencies due to longer AP. 
 
Ca2+ handling in dystrophic vs. normal muscle 
The rate of muscle relaxation is influenced by factors such as parvalbumin (PV) 
levels and Ca2+ uptake by the SR.  Studies evaluating levels of PV in dystrophic muscle have 
shown dissimilar results.  When measuring developmental changes in PV levels in dystrophic 
muscle, Sano et al. (133) reported a reduced amount of protein levels of PV in mdx mice 
compared to controls.  However, others have shown that PV turnover is increased in 
dystrophic muscle due to increased mRNA levels, but no data on PV protein levels w r  
reported (61).  The increased levels of PV mRNA might be a compensatory mechanism due 
to higher resting Ca2+.  Dystrophic muscle is known to have impaired Ca2+ uptake due to 
reduced SERCA activity (87; 51; 94; 41).  Kometani and colleagues demonstrated that the 
rate of relaxation of the EDL of mdx mice is slower compared to controls and this due to 
reduced SR Ca2+ uptake (94).  In 1988, Tuner et al. (148) demonstrated that the mean half 
decay time for Ca2+ transients is much longer in dystrophic muscle compared to controls.  It 
has been shown that treatment of dystrophic SMF with taurine or CK, increases SERCA 
activity which consequently speeds SR Ca2+ uptake (48; 127).  Moreover, the overexpression 
of SERCA improved the dystrophic phenotype in the mdxmice (69; 114).  This impaired 




worsening of the disease.  Therefore, improving SERCA activity and Ca2+ uptake could be a 
potential target in improving DMD. 
Results from the present study demonstrate that Fura-2 peak clearance is not different 
between mdx and controls, but that SMFs from Utr-/-/mdx mice take longer to clear Fura-2 
peak compared to controls.  Moreover, a trend for differences between mdx and Utr-/-/mdx 
was found for 50Hz.  Nevertheless, findings should be carefully evaluated.  The present study 
did not measure SR Ca2+ uptake or SERCA activity; thus, Ca2+ uptake was estimated based 
on 75% clearance of the total Fura-2 peak at 50 and 120Hz.  It is known that most of the Ca2+
binds initially to PV after muscle contraction and after that it is taken up by the SR Ca2+ 
ATPase to allow muscle relaxation (133).  In the current study we could not differentiate 
between PV binding and SR Ca2+ uptake, although this difference is most likely due to SR 
function since the SR pumping capacity controls the slower steady state removal of Ca2+ in 
the latter part of the Ca2+ transient (156).  As proposed by Andrade and colleagues (10), the 
slow final phase of Ca2+ decline after tetanus (Ca2+ “tail”) can be used to estimate SR Ca2+ 
pump function.  Therefore, the evaluation of Ca2+-t ils can give a more reliable measure of 
Ca2+ uptake. 
No previous study has evaluated Ca2+ uptake in SMFs from Utr-/-/mdx mice.  
Although it could be hypothesize that Utr-/-/mdx fibres might have greater impairment in SR 
Ca2+ function, the lack of studies evaluating key components related to muscle relaxation (PV 
levels and SERCA activity) in these animals, limit a conclusions about their SR Ca2+ control. 
 
Increase in resting Ca2+ during fatigue 
Although we expected a greater increase in resting Ca2+ during fatigue in both 
dystrophic mouse models compared to controls, no differences were observed.  This was 




single tetanus.  Therefore, it would be expected that impaired Ca2+ upt ke would contribute 
to a much greater increase in resting Ca2+ during fatigue in dystrophic SMFs.  Yet, increases 
in resting Ca2+ during fatigue were similar between all mouse strains.  We suggest that lack 
of differences could be due to the time between muscle contractions during fatigue.  The 
shortest time between fatiguing contractions was one minute, which seams to be en ugh time 
to allow clearance of most Ca2+ in all mouse strains.  Thus, the slower rate of Ca2+ clearance 
in the Utr-/-/mdx was in the millisecond range (see Figure 12).  Therefore, we can hypothesize 
that if the time between contractions decreased (i.e. 1 every 0.5 sec), then differences would 
be observed.  
 
Effects of calpain inhibition in dystrophic muscle 
 Calpains are non-lysosomal Ca2+- ctivated proteases that, when activated, participate 
in the breakdown of muscle constituents.  Due to improper Ca2+ handling in dystrophic 
muscle, with higher resting Ca2+ and increased Ca2+ influx during muscle contractions, it has 
been suggested that calpains could be one of the causes for the severe muscle pathology 
experienced by DMD patients.  Therefore, studies have evaluated the treatment of mdx mice 
with calpain inhibitors but results have been inconclusive (135; 14; 140; 27).  Differences in 
the type of calpain inhibitor used (leupeptin or calpastatin), mode of administration, and 
length of treatment (30 days vs. 6 months), explain differences in these results.  Badalamente 
and Stracher (14) gave direct leupeptin muscle injections in the mdx mice for 30 days, while 
Spencer and Mellgren (140), Briguet et al. (27) and, Selsby et al. (135) crossed the mdx with 
the calpastatin overexpressing mouse.  Also, in the study by Briguet and colleagues, mice 
were studies at 3 and 7 weeks of age (27).  Contrarily, in the studies by Selsby et al. (135) 





No studies have investigated the role of calpains during muscle contractions leading 
to muscle weakness in dystrophic muscle.  Therefore, we hypothesized that inefficie t Ca2+ 
control experienced in dystrophic muscle would be exacerbated during fatigue.  This would 
activate calpains and contribute to greater E-C coupling disruption in SMFs lacking 
dystrophin.  Based on our findings, the reduction in Ca2+ post-fatigue was eliminated with 
ALLN, suggesting the role of calpains in prolonged muscle weakness after fatiguing 
contractions in dystrophic muscle.  However, present findings need to be interpreted with 
caution.  In first place, stimulated muscle has not been examined to test if calpa ns were 
actually activated during the fatigue protocol.  Secondly, if calpains were to b  activated, we 
did not test if the calpain inhibitor was able to suppress calpain activation.  In order to 
address these issues, separate FBD muscles or strips from dystrophic mice have been exposed 
to different protocols and frozen for future analysis to address these limitations.  We will 
perform an enzyme assay to measure total caseinolysis (indicative of calpain activity) 
according to previously established protocols. 
  
Conclusion 
The present results show that E-C coupling disruption during fatigue is similar 
between SMFs from Utr-/-/mdx mice compared to SMFs from both mdx and CON mice; 
therefore the first hypothesis of the present project is rejected.  Moreover, obs rved findings 
demonstrate that the prolonged muscle weakness due to E-C coupling disruption is 
exaggerated in SMFs from Utr-/-/mdx compared to mdx and control mice; thus, our second 
hypothesis is accepted.  Lastly, inhibition of calpain activity attenuated the disruption of E-C 
coupling in mdx SMFs while a tendency was seen in Utr-/-/mdx SMFs.  Therefore, our last 




This study is the first to demonstrate the potential role of calpains in the prolonged 
muscle weakness experienced after fatigue in dystrophic muscle.  This adds evidence to 
support the hypothesis that improper Ca2+ handling contributes to the disease progression in 
DMD.  However, DMD is a complex disease that should be approached from various 
perspectives.  The multi-factorial aspect of the disease demands a combination of treatments 
targeting reductions in oxidative stress, increases antioxidant capacity, and improvements in 
Ca2+ handling in skeletal and cardiac muscle.  Many studies using the mdx mouse have 
demonstrated the efficacy of drug treatments in decreasing muscle damage, reducing fibrosis, 
and improving muscle function in dystrophic muscle.  Nevertheless, the mdx mouse does not 
manifest similar disease severity and progression as seen in DMD patients.  Therefore, future 
studies will need to evaluate the effectiveness of treatments (alone and/or combined) in better 



























Chapter 5: Review of Literature 
Skeletal muscle plasticity 
 Skeletal muscle is a very plastic tissue with the ability to respond to many different 
stimuli (81; 107).  Factors such as exercise training (i.e. endurance or resistance training), 
ageing, disuse (i.e. bed rest or immobilization), and various disease states (i.e. DMD or 
AIDS), induce changes in skeletal muscle.  Yet, skeletal muscle adaptations re unique to 
each individual which shows the complexity of its control.  For instance, this variability is 
fairly common in human exercise training studies, as it has been shown by Hubal and 
colleagues (83).  They evaluated men and women undergoing unilateral resistance training 
(all subjects trained under the same conditions) and results showed that the muscl
adaptations varied greatly between individuals (83).  While some studies aim to better 
understand mechanism driving skeletal muscle adaptations in healthy muscles, other 
investigations evaluate molecular and cellular alterations leading to changes in muscles in 
diseased states.  Hence, mechanisms inducing changes in diseased muscles are far less 
understood and more complex compared to normal muscle.  Therefore, two major challenges 
are faced by scientists when studying diseased muscles: the first challenge is related to 
understanding mechanisms leading to disease, while the second pertains to proposing 
interventions to improve muscle function and lessen disease severity.   
  
5.1 - Background on Duchenne muscular dystrophy 
Duchenne muscular dystrophy (DMD) is one of the most frequent and devastating 
types of muscular dystrophy that affects the human race (154).  Even though one in 3500
boys are born with the disease (2) and only a few cases affecting girls have been reported, 




patients (23; 144).  The reduced lifespan, not extending beyond the age of 30, is a 
consequence of progressive muscle wasting which leads to cardiac and respiratory failure 
(23).  Additionally, the loss of the ability to walk occurs in boys between the ages of six and 
12 (16).  However, the rate of progression of DMD may be different throughout the 
population diagnosed with the disease.  Some subjects become wheelchair bound by the age 
of 8 while some others are able to sustain walking until the age of 15 (93).  In addition to 
physical limitations observed in DMD, mental and biomechanical impairments have also 
been noted (23; 78; 161). 
Duchenne muscular dystrophy is named after the French scientist Duchenne de 
Boulogne, who reported the first case of cognitive problems in a child during the second half 
of the 19th century (23).  Yet, the main cause of the disease, lack of the protein dystrophin, 
was not known until the 1980’s (79).  The gene responsible for DMD is one of the largest 
genes in the human genome (23), and is expressed in skeletal, cardiac, and smooth muscle 
and brain (103).  The gene has at least seven promoters and is encoded by 79 exons spanning 
≥2.4 million base pairs (103).  Duchenne’s is an X-linked disease, meaning that the defective 
gene can be passed on to either male or female offspring, but its occurrence is mor common 
in the male population due to the single copy of the X chromosome (43).  Duchenne 
muscular dystrophy has been reported in females, but the presence of one healthy X 
chromosome reduces the severity of muscle degeneration when compared to that seen in 
males (111).  It is known that one in three new cases of DMD had no previous family histor
diagnosed, which demonstrates the complexity of a genetic disease (164). 
Due to progressive muscle damage and atrophy, DMD patients require continued 
intense medical attention.  The skeletal muscle of dystrophic patients has limited regenerating 
capacity and, as a result, is gradually replaced by fibrous and fat tissue (144).  Moreover, lack 




Patients with DMD undergo other medical difficulties.  In late stages, there is a higher risk of 
developing osteoporosis, urinary problems, and gastrointestinal complications (155).  
Duchenne muscular dystrophy patients also increase their chances of develping scoliosis at 
an earlier age due to muscle weakness and being wheelchair bound (43; 155).  The goalof 
medical treatment is to improve the quality of life and increase the patient’s lifespan.  The 
increase in the natural life span of those with DMD is due to multidisciplinary care 
coordinated by medical doctors, which include intense physical therapy, routine vaccinations, 
antibiotic prescriptions, and the use of corticosteroids to increase ambulation and slow the 
disease progression (155). 
Children with DMD undergo kinetic and kinematic adaptations due to the progressive 
muscle weakness (65).  Therefore, certain muscle groups are used more in order to 
compensate for the decrease in force and increase of stiffness of other muscles.  As proposed 
by Gaudreault and colleagues (65), ambulation and posture support are maintained i  patients 
with DMD by the hip and plantar flexors, and the hamstring group.  The loss in range of 
motion, or joint contractures, follows muscle weakness and has relevant contribution to 
physical impairments in DMD (65).  Thus, the outcome of joint contractures is an increased 
resistance to passive stretch in some joints (65).  Bakker et al. (16) proposed that the 
decreased muscle strength in ankle dorsiflexion and extension of the hip may be key 
indicators of ambulation loss in DMD.  Additionally, the same group suggested that 
information about ambulation restriction in patients with DMD is very limited (16).   
The effect of exercise training in DMD has been controversial.  It has been proposed 
that increasing muscle quality might be beneficial for children with DMD.  Strength 
improvements have been reported in the literature, but restricted methodologies and subject 
selection still prevent conclusive findings (93).  It is known that contractions hat stretch the 




benefits from muscle shortening contractions, or concentric exercise, may be useful to 
preserve muscle strength in children with DMD (93; 136; 169) without damaging the muscle.  
Strengthening exercises prescribed for patients with DMD should aim to decreas  the 
progression of muscle weakness rather than generate increase in strength (93).  Decreasing 
disease progression may prolong the patient’s life, and enhance their quality of life. 
However, exercise prescription for patients with DMD still needs further invstigation in 
order to adequately assess its potential benefits. 
 
5.2 - Mouse models for DMD 
The most used mouse model for muscle degeneration studies until the early 1980’s 
was the dy and dy2J mutants.  However, issues were raised about their similarity with DMD
(28).  It was not known if these animals were either myogenic or neurogenic in origin (28).  
Also, dy mutants demonstrate paralysis of their hind limbs between 3 and 4 weeks of age 
with an increased fragmentation in atrophied muscle fibres (28).  In 1984, Bulfield and 
colleagues published an investigation that would greatly add to studies investigating the 
underlying mechanisms of DMD (28).  The authors were the first to describe the mdx mouse, 
an animal with a natural mutation in the X chromosome from an original colony f 
C57BL/10 (28).  The group reported that these animals had high levels of CK and pyruvate 
kinase, and demonstrated similar muscle histological lesions as DMD patients (28).  After 
their discovery, hundreds of studies used the mdx mice to evaluate the underlying 
mechanisms in DMD.  Studies have shown that the mdx mouse has decreased muscle specific 
force (1), increased damaged during lengthening contractions (112; 169), increased 
macrophage accumulation, and increased fibrosis with aging (88).  However, the mdx mouse 




progression as seen in humans is the diaphragm (143).  The mdx mice overexpresses 
utrophin, a protein with similar role as dystrophin, and that could be the reason for a normal 
lifespan (122). 
It has been suggested that animals lacking both proteins, dystrophin and utrophin, 
would be a better model for DMD patients (37).  To generate the double mutant mouse,
Deconinck et al (50) first generated the Utr-/- mouse (49) and then crossed the Utr-/- into the 
mdx C57BL/10 background.  Briefly, female C57Bl/10 mdx mice mated with male Utr-/- and 
resulted in the F1 generation containing utrophin heterozygous mice and either mdx 
heterozygous (females) or mdx male hemyzygous (50).  Then, three other generations were 
crossed to generate the Utr-/-/mdx male mouse (50).  Contrarily from the mdx mouse, the Utr-/-
/mdx have altered neuromuscular and myotendinous junctions, early onset of damage in the 
diaphragm, joint contractures, kyphosis, and premature death by the age of 20 weeks (50).  
Yet, the small number of studies comparing the two animal models limitsthe conclusion 
about which animal model is better for DMD studies. 
The normal lifespan of the mdx mice has been related to continued satellite cell 
function.  After an episode of muscle damage, satellite cells are activated, thus dividing and 
producing myoblasts that fuse at the site of muscle injury (30).  Patients with DMD have 
great loss in functional muscle stem cells, while this is not as severe in the mdx mice (131).  
In a recent study, Sacco and colleagues reported that mdx mice also lacking the RNA 
component of telomerase (mdx/mTR), an enzyme related to maintaining telomere length, 
have similar disease progression as seen in DMD patients (131).  The similar d sease 
progression occurs due to the reduced size of telomeres, which are DNA repeats sponsible 
for maintaining genomic stability (131).  The study also demonstrated that satelli e cel  




Furthermore, mdx/mTR could be a better mouse model for future studies evaluating the 
underlying mechanisms affecting the muscle of dystrophic patients. 
 
5.3 - Calcium handling in dystrophic muscle 
 
Intracellular calcium (Ca2+) participates in the process of force generation and 
controls the activity of signaling molecules.  Abnormalities in Ca2+ control, especially 
increased Ca2+ levels at rest, have been implicated in making skeletal muscle cells more 
prone to necrosis (41) as well as activating Ca2+ dependent proteases (119).  Several studies 
have investigated [Ca2+] i in dystrophic muscle but results have been somewhat inconsistent.  
The purpose of this section is to discuss the current knowledge on [Ca2+] i in muscles lacking 
dystrophin. 
 
5.3.1 - Evidence of higher intracellular Ca2+ nd SR Ca2+ dysfunction 
Early studies have shown that muscle biopsies from DMD patients have increased 
Ca2+ content.  Bodensteiner and Engel evaluated the localization of Ca2+ in muscle samples 
from DMD patients and individuals with other myopathies.  Muscle samples were stained via 
von Kossa method, with alizarin red, and with glyoxalbis-(o-hydroxyanil) to measur  Ca2+ 
positive fibres; results demonstrated that more than 40% of DMD muscle fibres were Ca2+ 
positive while this was rarely found in other myopathies (24).  This was further confi med by 
Cornelio and Dones (39).  In addition to Ca2+ ssessment, the authors also performed the 
staining for albumin (a marker of extracellular fluid inflow) in muscle lacking dystrophin 
(39).  The amount of albumin was also higher in muscle samples from DMD patients 
compared to samples from individuals with other muscle diseases (39).  Others hav  used 
fluorescent dyes to evaluate [Ca2+] i in the dystrophic cells.  Fluorescent dyes, such as Fura-2, 




Bodensteiner and Engel (24) and Cornelio and Dones (39).  Mongini et al. used the 
fluorescent dye quin 2 to measure resting and peak free Ca2+ in cultured dystrophic muscle 
samples.  Results demonstrated that resting and peak free [Ca2+] i were higher in dystrophic 
cells compared to controls (113). 
Intracellular calcium levels were also evaluated in the mdx mouse.  The increased 
resting [Ca2+] i reported by Mongini et al. (113) was also confirmed by others, but in SMFs 
from dystrophic animals (14; 82).  Yet, no differences in [Ca2+] i levels between mdx muscle 
fibres and controls have also been reported (61; 102; 126).  Most of the discrepancies in 
findings have been linked to a) differences in the methods applied for the use of Fura-2, b) 
age of the animals, and c) different muscles assessed. 
The increase in resting [Ca2+] i suggested a potential impairment in Ca
2+ handling by 
the sarcoplasmic reticulum (SR).  The SR is a major muscle organelle responsible for Ca2+ 
storage, release, and uptake.  Moreover, the Ca2+ is released from the SR by the opening of 
the ryanodine receptors (RyR), and then eventually cleared from the cytoplasm by SR Ca2+ 
pumps (SERCA).  Most of the Ca2+ located in the SR is bound to calsequestrin, and it has 
been reported that calsequestrin-like proteins in the SR of muscles lacking dystrophin are 
reduced (42).  The SR is one of the key regulators of [Ca2+] i, nd appropriate cycling of Ca
2+ 
is required for muscle contraction and relaxation.  It has been shown that SR function is 
altered in DMD.  Isolated SR from dystrophic muscle has decreased velocity of Ca2+ uptake 
after electrical stimulation compared to controls (87).  However, the Ca2+ sensitivity of 
SERCA is not changed between controls and mdx mice (87).  Divet and Huchet-Cadiou (51) 
reported slower Ca2+ uptake by the SR in dystrophic muscle, but the authors suggested 
differences between fast and slow twitch muscles.  Furthermore, it has been reported that the 
levels of Ca2+-ATPase of fast-twitch skeletal muscle sarcoplasmic reticulum (SERCAla) is 




Different drugs can improve SERCA activity.  Elevations in the levels of taurine have 
been shown to increase the uptake of Ca2+ by SERCA in normal muscle (84).  This was later 
tested in mdx muscle fibres and results pointed to the beneficial effect of taurine 
supplementation on E-C coupling function, which was linked to improved SR Ca2+ upt ke 
(48).  Also, increasing the levels of CK in cultures of mdx myotubes has been shown to 
improve Ca2+ uptake, while not affecting Ca2+ entry from the extracellular space or Ca2+ 
efflux (127).  Lately, studies have reported an improvement in dystrophic phenotype by 
overexpressing SERCA1 in dystrophic mice (69; 114), but replication of findings in animals 
models with similar disease progression as seen in humans is needed.  Nevertheless, Morini 
and colleagues (114) studied the diaphragm of the mdx mouse, the muscle with greatest 
similarity in muscle pathology to human disease, and demonstrated increased SERCA1b 
levels (50% more compared to mdx mice) which correlated with improved force recovery 
after eccentric contraction.  Another SR Ca2+ dysfunction present in dystrophic muscle is 
related to RyR.  Takagi and colleagues (145) evaluated Ca2+ control by the SR and results 
showed an increased leakiness of Ca2+.  This has been linked with increases in resting Ca2+
levels, and further related to impaired Ca2+ release, which affects E-C coupling (48).  Thus, 
the prolonged increase in resting Ca2+ levels can contribute to the saturation of SERCA (48).  
In 2009, Bellinger and colleagues demonstrated that RyR of mdx mice are hypernitrosylated.  
The hypernitrosylation of RyR increased SR Ca2+ leakage by depleting the channel complex 
of calstabin 1 (calcium channel stabilizing binding protein) (22).  Furthermor, the 
hypernitrosylation of RyR with depletion of calstabin 1 and increased SR Ca2+ leakage is 







5.3.2 - Stretch-activated channels and Ca2+ levels 
The higher resting [Ca2+] i levels in DMD have been associated with stretch-activated 
channels that allow greater influx of Ca2+ during eccentric contractions.  For many years 
scientists have defended the idea that the lack of dystrophin increases chances of membrane 
tear during muscle contractions, thus increasing influx of Ca2+ from the extracellular space.  
The movement of large proteins, such as CK and albumin, through the cell membrane 
suggested that membrane defects might result from tears in the membrane (109).  In 2000, 
Alderton and Steinhardt (3) reported an increased Ca2+ influx in dystrophic myotubes, which 
was shown to be inhibited with Ca2+ channel antagonists, suggesting that Ca2+ w s probably 
not coming in the muscle through membrane tears.  Also, although muscles are more liable to
damage due to eccentric contractions and this damage is more pronounced in dystrophic 
muscle (169), it has been shown that Ca2+ entry in isolated SMFs of mdx mice occurs via 
channels rather than membrane tears (169).  Stretch-activated Ca2+ channel blockers greatly 
reduced the influx of Ca2+ in the mdx mice following eccentric contractions (169).  Thus, 
Ca2+ channel blockers such as streptomycin and the spider venom toxin GsMTx4 reduced the 
increase in resting [Ca2+] i, with eccentric contractions and partially suppressed the decline in 
tetanic [Ca2+] i and force (169).  The oral administration of streptomycin also demonstrated 
potential benefits to DMD, since muscles from treated animals had decreased central 
nucleation (a marker of muscle damage) compared to non-treated mdx mice (169). 
 The increased mechanosensitive channel activity has been suggested as a cause of
increased Ca2+ influx in DMD.  In 1994 Franco-Obregon and Lansman showed that the 
resting activity of mechanosensitive ion channels is elevated in dystrophin-deficient muscle 
compared to controls (59).  Moreover, it was shown that these mechanosensitive channels are 
the store-operated channels belonging to the transient receptor potential canonical (TRPC) 




(150).  Antisense based inhibition of 3 types of TRPCs (TRPC 1, 3, and 6) decreased Ca2+ 
influx in dystrophic fibres by 90% (150).  Blockers to stretch-activated channels have shown 
dramatic improvements in preventing an increase in [Ca2+] i and minimizing the reduction in 
isometric force (66; 169).  Thus, these blockers reduced the increase permeability occurring 
due to stretch contractions, which demonstrated that the increase permeability occurred as a 
secondary consequence to Ca2+ entry (160).  It was further shown that the TRPC1 gene is one 
the candidates for being involved in the increased Ca2+ entry (66).  Gervasio and colleagues 
(66) demonstrated that TRCP1 has a role in DMD by showing that TRCP1 binds to caveolin-
3 (scaffolding protein related to binding and regulating other proteins) which increased Ca2+ 
entry through the plasma membrane.  Moreover, the levels of TRPC1 and caleolin-3 are 
higher in mdx mice compared to controls (66).  Another gene suggested to participate in the 
increased Ca2+ influx is the transient receptor potential vanilloid 2 (TRPV2).  The 
downregulation TRPV2 was shown to decrease Ca2+ entry and ameliorate some features of 
DMD (85). 
Interestingly, the stretch-activated channels are not directly activated by stretch and 
studies have demonstrated that reactive oxygen species (ROS) are a majorctivator (71; 
125).  The increased ROS production is one of the characteristics in DMD (128).  Treating 
dystrophic muscle fibres with ROS greatly increases [Ca2+] i levels (66) and is inhibited by 
streptomycin, which supported the idea that the activation of the stretch activated channels is 
dependent on ROS (66).  In 2009 Millay and colleagues showed that overexpression of 
TRPC3 was sufficient to induce similar muscle phenotypic changes to those occurring in 
DMD (110).  Although the control of Ca2+ channels is thought to be one of the potential 
targets for treating dystrophic muscles, it has been shown that such treatment has great 
limitations.  The long-term blocking of Ca2+ channels streptomycin in the mdx mice was 




sarcolemmal stability in skeletal muscle (86).  However, no positive effects were reported in 
either diaphragm or heart muscle, in fact heart pathology was worse with prolonged 
inhibition of Ca2+ channels (86).  Findings from the study demonstrate the importance of 
evaluating the long-term effect of drug treatments (86), and also testing muscles that have 
same disease progression as seen in DMD. 
 
 
5.4 - Calpains 
The maintenance of muscle size is dependent in the balance between protein 
synthesis and break-down.  The decrease in muscle mass has been linked to increased 
protein turnover, which consequently decreases muscle function.  It is known that 
catabolism of proteins and amino acids are increased during moderate exercise (129).  On 
the other hand, the rates of protein synthesis surpass protein breakdown after exercise
(129).  This increased protein degradation and amino acid oxidation, during exercise, 
have been attributed to two types of proteases, the lysosomal proteases (i.e., thecathepsin 
family) and the non-lysosomal proteases (i.e., calpains) (21).  Yet, some evidence 
suggests that the activity of such proteases is only increased post-exercise, and not during 
exercise (119; 89).  Nonetheless, the specific role of proteases, specially the non-lysosomal 
calpains, has been the focus of many research groups.  Thus, calpains have received great 
attention due to the implication of their activation in various disease states, such a  
sarcopenia, diabetes, cachexia, acquired immune deficiency syndrome (AIDS), and 
muscular dystrophy (20; 146; 167; 92; 11; 137).  This section will focus in explaining the 






5.4.1 – Calpains: definition, isoforms, structure, and skeletal muscle location 
 The calcium-dependent cysteine proteinase, or calpain, was first discovered in the rat 
brain but later studies demonstrated its presence in various tissues and species (73; 90; 68).  
Over 14 types of calpains have been identified, but the ones most well characterized are 
calpain 1, calpain 2, and calpain 3 (also known as p94 or CAPE3) (137).  Calpain-1 is 
commonly called µ-calpain while calpain-2 is known as m-calpain, names given bas d on the 
amount of Ca2+ necessary for their activation (116).  Most calpains are ubiquitously 
expressed while calpain-3 has been thought to be exclusively expressed in muscle (116; 137).  
However, studies by Konig et al. (95) and Marcilhac et al. (106) have indentified calpain-3 in 
other tissues.  The presence of calpain-3 in skeletal muscle might be reat r than calpain-1 
and calpain-2, since it has been shown that mRNA levels of calpain-3 are ten times greater 
compared to calpain-1 or calpain 2 (138). 
Calpain-1, -2, and -3 share a similar structure.  Calpain-1 and calpain-2 are 
heterodimers containing a large subunit, 80kDa, and a small subunit (approximately 28kDa) 
– the small subunit is removed to allow the proteolytic activity of calpain-1 and -2 (115; 
116).  Calpain-3, on the other hand, has a monomeric structure of 94kDa (45; 116).  All three 
calpain isoforms are similar in structure by possessing four domains: i) the N-terminal 
domain containing the site for autolysis; ii) the proteolytic domain (45; 138); iii) a C2-like 
region involved in membrane phospholipid interaction; iv) the Ca2+-binding site which 
contains five EF-hand domains (138).  Calpain-3 also has three inserted sequences (NS, IS1, 
and IS2), which are not present in the other two calpains (116).  The small subunit preset in 
calpain-1 and calpain-2 has two different domains - domain V contains a site for autolysis 





Although calpain-1, -2, and -3 are present in skeletal muscle, their location wi hin the 
muscle differs.  The location of calpain-1 and calpain-2 within skeletal muscle has been 
investigated since the 1980’s, but differences in location were identified du  to the different 
techniques used for isolating, staining, and fixing of muscle samples, as well as lack of 
antibodies specific for each calpain.  Barth and Elce (17) located calpain-2 in the 
sarcolemmal region while other investigators reported its location near the Z-line and 
sarcolemma (46; 68).  According to Yoshimura et al. (170) the antisera used in th se s udies 
demonstrated cross-reactivity with calpain-1, which could have interfered with the findings.  
Therefore, Yoshimura and colleagues (170) performed a more thorough methodological 
approach using a double affinity purified monospecific antibody to calpain-1, which did not 
cross-react with calpain-2, to localize calpain-1 in skeletal muscle of rats. Results 
demonstrated that calpain-1 was localized in the I-band region, but was not exclusively 
associated with the Z-line (170).  Calpain-2 has been mostly found in the cytoplasm, whereas 
calpain-3 has been described as being found in either the triad junction, SR membrane, or 
localized in the myofibrillar structure (attached to titin) (96; 91).  Others have demonstrated 
that calpain-3 is bound to the M-line of titin, but no studies have replicated the findings (64).  
In a study by Murphy and Lamb (118) a novel technique was used to better determine the 
location of calpain-3 within skeletal muscle.  Skinned fibres (fibres with the sarcolemma 
removed) were exposed to triton X-100 and then both wash solution and fibre were run on a 
western blot to analyze the proteins in each fraction (118).  Results demonstrated that 
calpain-3 is not bound in the triad junction or SR, but rather tightly bound within the 
contractile protein in a location corresponding to the N2A line on titin (118).  Therefore, 
calpain-3 might be related to the control of titin, consequently influencing muscle contractile 





5.4.2 - Activation of calpain-1 and -3 depends on increases in [Ca2+] i 
Calpains do not perform their proteolytic role unless they are activated by increases 
in [Ca2+] i.  Calpains become activated by the autolysis that occurs at the N-terminal part of 
both subunits (45).  This leads to the formation of a 78 kDa and 76 kDa subunit for m- and µ-
calpain, respectively (45).  After the initial autolysis the [Ca2+] necessary for further 
proteolysis is reduced (132), but the concentration needs to be maintained above resting 
levels (120).  There is evidence demonstrating that the interaction between calpai s nd 
phospholipids reduce the [Ca2+] necessary for the activation of calpains, suggesting that they 
can be activated at lower, more physiological Ca2+ concentrations (132; 38).  The levels of 
both substrates in these studies, however, were much greater than in vivo concentrations, 
illustrating the limitations of most studies investigating the [Ca2+] requirement for calpain 
activation. 
Other studies have used more physiological levels of Ca2+.  Verburg and colleagues 
(152) used skinned fibres to the test if calpain-3 activation played a role in disruption of E-C-
coupling and results showed that calpain-3 was activated after brief exposure (1 to 3 minutes) 
of 2 to 8µM of Ca2+.  Increasing the [Ca2+] to ~1µM or more for 3 minutes caused an 
irreversible reduction in depolarization induced force production (152).  This reduced for  
production was further suppressed with the calpain inhibitor leupeptin (152).  Fibres exposed 
to Ca2+ and stretch showed proteolysis of titin, which was linked to the activation of calpain-
3 (152).  The autolysis of µ-calpain has also been evaluated.  The exposure to low [Ca2+] (≤ 
200nM) for even 1 hour does not induce the autolysis of µ-calpain, but if the levels are raised 
to 5µM for only a few minutes a good fraction is autolyzed (120).  It is thought that at rest or
during normal activity the [Ca2+] i does not reach the required level for the activation of µ-
calpain in muscle, but in situations of eccentric damage and disease (i.e. DMD) the entry of 




Studies investigating the activation of calpains linked eccentric damage and influx of 
Ca2+ to calpain autolysis.  Although  Belcastro (19) reported a very high Ca2+ sensitivity and 
activation of calpains (10% and 50% of maximal proteolytic activity at 100mM and 1µM 
Ca2+) following an exercise bout in rats (running until exhaustion), the methods used for 
calpain isolation and/or the non-physiological solutions may have influenced the findings 
(120).  If the activation of calpains occurred at low Ca2+ concentrations, then skeletal muscle 
would be constantly going through degradation of proteins is response to minimal stress 
(120).  Furthermore, the [Ca2+] i does not reach very high levels during concentric exercise, 
while [Ca2+] i reach high levels in response to eccentric contractions.  Thus, an “all-out” 
exercise bout (cycling) in humans did not activate either calpain-3 or calpain-1 (119), while 
humans undergoing a single bout of eccentric exercise showed the activation of calpain-3 
(117).  Therefore, it was thought that eccentric contractions, which elicit an increase in Ca2+ 
influx, could lead to the activation of calpains.  In animals, eccentric damage was shown to 
disrupt contractile protein structure, reduce membrane stability, and decreas  force in 
muscles (171).  Yet, all these were mostly suppressed when the extracellular [Ca2+] was 
reduced to zero or when the muscle was treated with calpain inhibitor (leupeptin) (171).  
These findings suggested the role of eccentric damage and Ca2+ influx in calpain autolysis.  
Nevertheless, the damage due to eccentric contractions alone does not initiate the proteolytic 
activity of calpains.  As shown by Murphy and Lamb, lengthening contractions followed by 
increased Ca2+ influx leads to an increase in resting [Ca2+] i, which consequently activates 
calpain-3 (118). 
 
5.4.3 - Calpains and E-C coupling disruption 
Studies linking increases in [Ca2+] i with E-C-coupling disruption suggested the role 




uncoupling disruption has been suggested as a protective mechanism to avoid greater calcium 
dependent damage to muscle fibres (99).  Small increases (slightly above average) in [Ca2+] i 
near the triad junction has been shown to induce E-C coupling impairment (159).  This Ca2+-
induced uncoupling also takes place after prolonged small increases in resting [Ca2+] i (99).  
However, raising the [Ca2+] i to relatively high levels (approximately 1mM) for short period 
of time (ten seconds) also disrupts E-C coupling (99).   
Decreases in metabolite levels are not the cause of delayed muscle recov ry from 
fatigue.  Edwards and colleagues (55) reported a long lasting decrease in muscle force (more 
than one day) which was not caused by the depletion of high-energy phosphates or failure of 
electrical activity.  Further studies showed that the level of metabolies used in muscle 
contraction (i.e. creatine phosphate and ATP) were not the cause of this long-lasti  force 
deficit, since they are restored to normal values within 60 minutes (15; 55; 77).  Also, this 
mechanism is not related to decreased Ca2+ sensitivity or Ca2+ induced force-generating 
capacity (159; 33).  The decrease in low frequency force occurred as consequence of Ca2+ 
release failure, which happened due to interruption of coupling between voltage-sensor 
molecules (dihydropyridine receptors) and Ca2+ release channels (RyR) (33; 35; 99).  The 
long-lasting decrease in Ca2+ release is even more pronounced when [Ca2+] i re increased 
during fatigue stimulation (33).  In addition, greater E-C coupling disruption takes place if 
the increases in [Ca2+] i occur near the triad junction  (151).  The possible mechanism inciting 
E-C coupling disruption could be associated with activated Ca2+-dependent proteases which 
could initiate degradation of proteins in the triad junction (151). 
Sarcoplasmic reticulum Ca2+ uptake and release is linked to changes in E-C coupling.  
It has been shown that prolonged exercise decreases SR Ca2+ uptake in fast- and slow-twitch 
muscles by 20 to 40%, without affecting SR Ca2+ ATPase activity (57).  This leads to an 




subjecting muscle fibres to a long-lasting fatigue.  Thus, the increase in [Ca2+] i lasted for 
more than 30 minutes and averaged 40% more than normal (159).  As suggested by Lamb 
and Cellini (97), the reduced Ca2+ uptake and increased resting Ca2+ can be explained by high 
increases in Ca2+ levels during tetanus, which might increase the Ca2+ le kage from the SR.  
Therefore, the increased resting Ca2+ nd decreased Ca2+ uptake are factors which decrease 
SR Ca2+ release.  This prolonged increase in resting [Ca2+] i may induce the activation of 
calpains, which consequently induces E-C uncoupling even after the levels of metabolit s 
and ions achieve baseline values. 
 
5.4.4 - Calpains and Duchenne muscular dystrophy 
Turner and colleagues (148) reported increased resting Ca2+ levels, reduced SR Ca2+ 
uptake, and elevated resting Ca2+ during SMF stimulation in dystrophic mice.  They assessed 
whether proteolysis was involved by exposing SMF to different [Ca2+], nd found that 
dystrophic animals had much greater net breakdown of proteins compared to controls (148).  
The dysfunctional Ca2+ handling (in muscle as well as myotubes) combined with the 
evidence of increased proteolytic activity in dystrophic muscle pointed to the potential role of 
calpains in DMD (113; 148; 58; 75).  In 1995, Spencer and colleagues reported for the first 
time direct evidence linking calpains to the pathology of DMD (139).  The levels of calpains 
were shown to be regulated differently during necrosis and regeneration of dystr phic muscle 
(139).  At peak necrosis, the levels of calpain-2 protein were increased, yet, the levels of the 
autolyzed isoform (78 kDa) were not changed, indicating that while the amount of calpain-2 
was higher, the activity was not increased (139).  The levels of calpain-1 were not increased 
during necrosis, but the amount of the autolyzed isoform (76kDa) was higher (139).  Lastly,
the levels of autolyzed calpain-1 and calpain-2 went back to normal after the muscle was 




degeneration and regeneration (142).  Spencer & Tidball reported that the translocation of 
calpains to different areas of muscle fibres was associated with enzymatic cleavage, thus 
supporting the hypothesis of calpain activation during different stages of muscle regeneration 
and degeneration in DMD (142).  The distribution of calpains is mostly similar between mdx 
and control mice in the prenecrotic stage, but mdxfibres demonstrated a higher amount of 
calpains associated with the plasma membrane (142).  During the necrotic stage in dystrophic 
muscle, the majority of the calpains are found in the cytoplasm (142). 
The effect of treating muscles lacking dystrophin with different calpain inhibitors has 
given some insight into the relationship between calpains and DMD.  Intramuscular 
administration of leupeptin showed a decrease in muscle degeneration is mdx mice, which 
pointed to the potential effect of calpain inhibition in treating DMD (14).  Yet, th  animals 
were only treated for 30 days and the effects of multiple direct muscle injectio s were not 
accounted for.  In a study investigating the hydrolysis of a calpain substrate in normal and 
dystrophic myotubes, Alderton and Steinhardt (3) showed that after the development of 
contractile activity, dystrophic myotubes had higher levels of calpain hydrolysis compared to 
normal myotubes.  This high level of hydrolysis was dependent on external Ca2+, and could 
be abolished by a calpain inhibitor (calpeptin) (3).  The authors also demonstrated th t the 
increased Ca2+ levels occurred due to abnormal activity of Ca2+-specific leak channels, which 
could be reduced by using a Ca2+ channel antagonist (3).  Although these studies evaluated 
the levels of calpains and their cleavage in dystrophic muscle, they did not assess if calpain 
activation precedes or occurs as consequence of cell death (140). 
Spencer and Mellgren (140) generated m x mice that overexpressed calpastatin, a 
potent endogenous inhibitor of calpains, to evaluate differences in the dystrophic phenotype 
due to calpain inhibition.  The overexpression of calpastatin was sufficient to ameliorate the 




reduced muscle necrosis, regenerating areas, and membrane damage compared t  mdx mice.  
Thus, the results demonstrate that calpains acted downstream of the primary muscle defect in 
DMD (140).  Nevertheless, in 2008 another study using the CS Tg/mdx reported that 
increases in muscle calpain inhibitor did not ameliorate the dystrophic phenotyp  (27).  Thus 
both groups, mdx and CS Tg/mdx, had similar percentage of muscle necrosis and 
regenerating areas.  Yet, the authors showed a histological improvement by inhibiting the 
ubiquitin-proteasome pathway (27).  In 2010, Selsby and colleagues used a technique to 
increase leupeptin concentration in mdx skeletal muscle by using carnitine to carry leupeptin 
in skeletal muscle but results did not show any improvement in mdx mice after 6 months of 
treatment (135).  These results suggest that while calpains might have an cute effect in 
muscle function, that chronic suppression is not effective in preventing muscle damage or 
that other mechanisms play a role in the progression of the muscular dystrophy. 
 
5.5 - Fatigue mechanisms in skeletal muscle 
 Muscle fatigue is characterized by the inability of the muscle to generate force (156).  
This event takes place when skeletal muscle undergoes constant stimulation, followed by 
decline in function.  Many mechanisms have been proposed to influence fatigue (i.e. 
depletion of substrates such as glycogen, accumulation of metabolites, reduced Ca2+ r lease 
and reduced Ca2+ sensitivity of the myofilaments, etc.), but findings have been somewhat 
inconsistent (44).  Results from some investigations are limited in their application due to 
unrealistic (non-physiological) concentrations of metabolites and ions (4).  However, other 
studies have been carefully designed and results are more applicable; yet replication of 




studies and select well-designed investigations; rather, the aim of the pres nt section is to 
discuss the recent progress in understanding the underlying mechanisms of fatigue.
Studies investigating the effects of fatigue on force production have taken place since 
the 1970’s.  When investigating muscle force recovery after fatiguing contractions, Edwards 
and colleagues (55) reported that the muscle’s ability to generate force at high frequency after 
fatigue was reduced for approximately 20 minutes, while the force production at low 
frequency stimulation was greatly reduced for over 1 day.  This was a very interesti g finding 
regarding differences in the ability of the muscle to respond to low and high stimulation 
frequencies after fatigue.  The authors also evaluated changes in muscle force between 
muscles subjected to low vs. high frequency stimulation during fatigue, and results 
demonstrated that the decrease in initial force was greater when the muscl wa  stimulated at 
low frequency compared to high frequency (55).  Moreover, the deficit in low-frequency 
force was not attributed to decreases in the levels of high-energy phosphates or f ilure of 
electrical activity as assessed by electromyography (55). 
To follow up in the previous study, Dawson and colleagues (47) used force 
measurements combined with phosphorus nuclear magnetic resonance as a technique to 
relate muscle functional changes to simultaneous biochemical and energetic alterations (47).  
Therefore, Dawson et al. (47) measured several different variables in the gastrocnemius 
muscle undergoing fatigue, which included: 1) isometric force development; 2) affinity for 
ATP hydrolysis; 3) rate of ATP hydrolysis; 4) changes in concentrations of creatine 
phosphate (CrP), ATP, free adenosine diphosphate (ADP), inorganic phosphorus (Pi), 
hydrogen ions (H+), and creatine (Cr) (47).  The mechanical changes during fatigue, as well 
as the decreases in force production and slower relaxation rate, were associated with the 
metabolic alterations in the fatigued muscle (47).  The relaxation rate was related to all 




Yet, Dawson and colleagues (47) suggested that some metabolites, such as Cr, CrP, and ATP, 
could be ruled as contributors to altered relaxation rate.  Further, decreases in ffinity of ATP 
hydrolysis (a theoretical measure of the maximum amount of work accomplished per mole of 
ATP hydrolyzed) during prolonged stimulation were caused by increased product 
concentration and not by decreases in ATP concentration (47).  Lastly, the authors concluded 
that the relationship between relaxation rate and ATP hydrolysis could be relat d to Ca2+ 
sequestration by the SR, since it is an ATP-dependent process, but the authors did n t 
measure SR Ca2+ uptake (47).  The link between biochemical and energetic alterations w th 
fatigue gave new insight into factors contributing for the decrease in muscle force, but some 
questions were still unanswered. 
Following the study by Dawson and coworkers (47), other groups investigated 
changes in muscle function during fatigue while applying different levels of vari us 
metabolites to skinned muscle fibre preparations where the sarcolemma is removed to allow 
direct access to the intracellular environment.  However, this set-up required application of 
exogenous Ca2+ and did not allow scientists to measure force responses in relation to normal 
E-C coupling processes.  In 1985, Grynkiewics, Poeni, and Tsien (72) published a study that 
changed muscle fatigue assessment.  They developed fluorescent dyes (i.e. Fura-2) that could 
be used to measure real time Ca2+ levels in intact cells for monitoring changes in intracellular 
Ca2+ simultaneously with cell function (72).  The development of new fluorescent dy s and 
the technique to dissect SMFs with the sarcolemmal membrane intact started a new era in the 
evaluation of fatigue, force, and intracellular Ca2+ levels.  By the early 1990’s more detailed 
analyses of the cellular mechanisms underlying muscle fatigue and its relationship to Ca2+ 
were possible. 
One of the methods to evaluate the causes of fatigue in skeletal muscle used SMFs 




Lannergren & Westerblad (100), who measured changes in isometric force in SMFs exposed 
to different temperatures.  In another study, Lannergreen and Westerblad (101) evaluated 
time to fatigue, force decline, acidification, and the effects of caffeine in force recovery in 
SMFs after fatigue exposure.  The fatigue protocol involved electrically stimulating SMFs 
with repeated tetani at 70Hz once every 3.8s (for 2 minutes), and then continually reducing 
the resting time between tetani until the fibre reached fatigue, with fatigue being defined  as 
30% of initial force (101).  Results demonstrated that endurance capacity of SMFs has great 
variability (between 2.5 to 24 minutes), but most fibres reach fatigue between 4 to 8 minutes 
(101).  Results demonstrated that caffeine has no effect on force production in the rested 
state, but causes fast and dramatic increase in force when administered aft r fatigue (101).  
Lastly, the authors exposed SMFs to increased levels of acidosis, which decreased time to 
fatigue, but was somewhat recovered with the addition of caffeine (101).  Furthermore, the 
two authors also identified three different phases of muscle fatigue: a) fast decline in tension 
to 90% of its initial recorded value (phase 1); b) plateau in tension production (phase 2); c) 
fast tension decline (phase 3) (101).  It was proposed that the decrease in force i phases 1 
and 3 of fatigue were due to different underlying intracellular mechanisms. 
Following these findings, Westerblad and Allen (156) performed a study in which 
they used a Ca2+ indicator, known as Fura-2AM, to assess [Ca2+] i in SMFs during fatigue.  
The study designed by Westerblad and Allen (156) was the first investigation combining the 
measurements of [Ca2+] i using Fura-2AM and tension in mammalian SMFs.  Results 
demonstrated an increase in resting (baseline) [Ca2+] i as the fatiguing stimulation continued, a 
fact that could not be explained by the authors at the time (156).  The investigator  also 
pointed out that early tension decline could not be rescued by caffeine application, suggesting 
that metabolic changes were influencing force production in phase 1 of fatigue (156).  




fast decline in force to 90% of its original starting value (156).  When discussng which 
possible factor could have influenced the fast tension decline in phase 3, the authors prop sed 
that an impaired activation of cross-bridges by reduced intracellular Ca2+ could explain this 
mechanism (156).  They supported their statement by demonstrating that application of 
caffeine, which elevated tetanic intracellular Ca2+ levels, was able to recover tension up to 
80% of its initial value (156). 
By the mid 1990’s groups of investigators had focused in studying the mechanisms 
influencing Ca2+ release and Ca2+ sensitivity of the myofibrillar proteins, as well as the effects 
of pH during fatigue.  Studies by Fryer et al. (60) and Owen et al. (121) suggested that 
reduction in Ca2+ release was influenced by both metabolic and non-metabolic factors.  
During the same time, it had been shown that pH influenced SR Ca2+ release (56), but other 
groups reported no effects (157).  Differences in the methods used for assessing SR Ca2+ 
release were probably the cause for discrepancies in findings.  While Favero et al. (56) used 
isolated SR from rabbit muscle, Westerblad and Allen measured SR Ca2+ rele se in intact 
SMF from mice.  Studies using more physiological temperatures demonstrated th t changes 
in pH had a reduced effect on SMF function (158).  However, differences in the 
methodological approaches and thus discrepancies in findings limited the conclusi s on the 
cellular mechanisms underlying muscle fatigue. 
Chin and Allen (34) suggested that the role of pH changes in muscle fatigue was 
fiber-type specific as well as intensity dependent.  The authors evaluated the differences in 
force, [Ca2+] i, and acidosis in SMFs exposed to different fatiguing protocols.  While the two 
different fatiguing conditions involved stimulating SMFs at 100Hz, the time between 
repeated tetani varied between protocols (34).  Their study compared the standard fatigue 
protocol, where fibres were stimulated once every 4s, then once every 3s, and so on, until 




protocol with only a very short (1s) rest period between tetani until force reached 30% (34).  
Fibres exposed to the higher frequency of tetani reached 30% of initial force faster than fibres 
exposed to the lower frequency of tetani (34).  However, the decrease in [Ca2+] i was more 
pronounced in SMFs exposed to low frequency fatigue (48%) compared to high frequency 
fatigue (35%) (34).  The faster decrease in force at high rate of tetani was ot due to Ca2+ 
release failure (34).  In order to assess E-C-coupling failure, SMFs were treated with caffeine 
(5mM), a Ca2+ release channel agonist, as soon as the fibre reached 30% of its initial force 
(34).  Caffeine was able to restore force in SMFs exposed to fatigue at low rate of tetani, but 
did not improve force recovery after high rate of tetani (34).  This demonstrates th  the 
reduced Ca2+ release during fatigue from rapidly occurring tetani, even with the addition of 
caffeine, is related to insufficient SR Ca2+ refilling (34).  Changes in pH were also evaluated 
during low vs. high intensity fatigue (34).  Results showed that high frequency tetani induced 
higher and faster increase in acidosis, which suggested that such mechanism plys a major 
role during the fatigue experienced when muscles are stimulated at high intensities with short 
recovery periods between tetani (34).  These results also demonstrated that Ca2+ sensitivity is 
reduced to a greater extent when muscles are exposed to higher acidosis (34). 
A broader attempt to characterize mechanisms affecting muscle fatigue was later 
undertaken by Danieli-Betto and colleagues (44).  They aimed to investigate if fatigue also 
caused continual modifications of SR and myofibrillar proteins that contributed to the 
decrease of tension in mammalian fibres (44).  Fast and slow-twitch fibres we  evaluated for 
SR Ca2+ release and uptake, SR caffeine sensitivity, and myofibrillar proteins Ca2+ ensitivity 
using a skinned muscle fibre technique (44).  Changes in myofibrillar protein properties, as 
well as SR function, are still present after the muscle fibre is skinned a d has its myoplasm 
replaced with a new physiological medium (44).  Maximal Ca2+ tension was the same in 




changes in Ca2+ sensitivity occurred due to modifications of myofibrillar proteins (44).  The 
study also showed that the SR of slow-twitch fibres accumulated Ca2+ at  faster rate when 
skinned immediately after fatigue compared to fibres skinned prior to fatigue (44).  
Additionally, both slow- and fast-twitch chemically skinned fibres maintained SR Ca2+ 
release patterns after fatigue (44).  On the other hand, Ca2+ removal in intact SMFs was 
slower which was explained by the increased metabolite levels in addition to p sttranslational 
modifications of SR Ca2+ pump and/or phospholamban (transmembrane protein that regulates 
SR Ca2+ pump activity ) (44).  Posttranslational modifications of proteins responsible for SR 
and myofibrillar properties play an important role in force decline of mamlian slow-twitch 
fibres during fatigue, but do not appear to influence fast-twitch muscle fatigue (44). 
High increases in [Ca2+] i can also induce reductions in muscle force during fatigue.  
Muscle excitation results in the release of high amounts of [Ca2+] i into the myoplasm, 
increasing intracellular Ca2+ concentrations from ~50nM to 1-2uM (156) .  Previous studies 
suggested that elevated [Ca2+] i itself plays a role in the development of long-lasting fatigue, 
but no previous study investigated if E-C coupling is disrupted by peak Ca2+ levels or the 
temporal accumulation of Ca2+ (33; 99; 151; 159).  The study by Verburg and colleagues 
(151) used mechanically skinned fibres in order to manipulate Ca2+ levels and evaluate its 
effect on E-C uncoupling, defined as a reduction in Ca2+ release and force production in 
response to excitation.  Results demonstrated that [Ca2+] i needed to be elevated by 2µM for at 
least one minute to elicit E-C coupling disruption in fast-twitch fibres (151).  Peak Ca2+, and 
not the temporal accumulation of Ca2+, was suggested to be the mechanism responsible for 
uncoupling (151).  Uncoupling was only affected when peak Ca2+ levels were reached near 
the triad junction, and not near the center of the cytoplasm, thus, this E-C coupling disruption 
was caused by the failure of signal transmission at the triad junction (151).  Furthermore, the 




elevated between one and three minutes and its level was similar to th t achieved during 
maximal force production; and 2) peak Ca2+ in the vicinity of the triad junction is above its 
normal level (151). 
Another study investigating potential mechanisms contributing to muscle fatigue was 
carried by Roots and colleagues (130).  The authors aimed to evaluate fatigue that followed 
either (a) repeated short isometric contractions, or (b) repeated concentric contractions at 
three different temperatures (10°C, 20°C, and 30°C) (130).  Repeated concentric contractions 
elicited greater force decrements in comparison to isometric contrations (130).  Single 
muscle fibres exposed to isometric contractions during fatigue had a lesser dcrease in force 
at 30°C (20%) than 10°C (30%) (130).  Moreover, there was a relationship between absolute 
power and temperature, with absolute power increasing by more than ten-fold from 10°C to 
30°C (20).  Their results also suggested that the reduction of power following fatigue was 
greater at 10°C and lower at increased temperatures (130).  Othershav  hown that pre-
fatigue tetanic force as well as force and [Ca2+] i reduction during fatigue,  followed similar 
patterns at 37oC and 43oC (130).  Although oxidative stress was higher at 43 °C, this increase 
did not contribute to premature fatigue (130). 
Numerous investigators have studied the potential mechanisms contributig to 
muscle fatigue, but findings are still somewhat inconclusive due to methodological 
limitations and differences in techniques used to assess fatigue mechanisms.  However, there 
is consensus across studies showing that factors such as intensity, duration, and typeof 
contraction influence muscle fatigue (4).  More recent studies are more carefully designed 
and tend to incorporate several variables, not just one, to understand the effect of combined 
mechanisms on muscle fatigue.  This has been shown in the study by Place and colleagues 
(124) where the authors evaluated the combined effects of temperature and oxidative stress in 




contraction patterns to evaluate how oxidative stress contributed to muscle fatigue at more 
physiological temperatures (130).  Studies following this pattern represent the future 
approach of evaluating factors contributing to muscle fatigue. 
 
5.6 - Summary  
Duchenne muscular dystrophy is one of the most severe types of muscular dystrophy 
affecting humans.  Although the main cause leading to DMD has been linked to the lack of 
protein dystrophin, many of the underlying mechanisms contributing to the increased mu cle 
damage and progressive loss of muscle function are still unknown.  Dystrophic animals, such 
as the mdx mouse, have been used in studies investigating potential disease treatments.  
However, the mdx mouse has a relatively normal lifespan, which is explained by the 
overexpression of utrophin and increased satellite cell function.  Moreover, mice lacking both 
dystrophin and utrophin are thought to be a better model for DMD, but not many studies have 
evaluated differences between double mutants (animals lacking dystrophin and utrophin) vs. 
mdx mice. 
Impaired intracellular Ca2+ handling is thought to be one the potential mechanisms 
contributing for DMD.  Studies have shown that dystrophic muscle has higher resting [Ca2+] i, 
impaired SR Ca2+ control (increased SR Ca2+ leakage and slower SR Ca2+ uptake), and 
increased influx of Ca2+ from the extracellular space.  Moreover, poor Ca2+ h ndling has been 
linked to activation of Ca2+-activated proteases known as calpains.  Skeletal muscle of 
dystrophic animals has reduced fatigue resistance due to greater disruption of E-C-coupling 
during fatigue.  This greater E-C-uncoupling during fatigue is associated with poor Ca2+ 
handling and the possible activation of calpains.  However, no study to date has evaluated if 
calpains play a role in the prolonged E-C-coupling disruption experienced by dystrophic 




and the prolonged muscle weakness experienced after fatigue between the mdxand double 

















































Time to fatigue – comparison between all groups (both treatments – vehicle and ALLN) – 




 Sum of Squares df Mean Square F Sig. 
Between Groups 356220.323 2 178110.161 1.376 .265 
Within Groups 5048674.207 39 129453.185   
Total 5404894.530 41    
 
1= mdx 2= Utr-/-/mdx  3= con 
Multiple Comparisons  
VAR00048 
Tukey HSD 
(I) VAR00049 (J) VAR00049 
Mean 
Difference (I-J) Std. Error Sig. 








2.00 255.32468 156.13311 .243 -125.0636 635.7130 
3.00 95.06643 125.86569 .732 -211.5811 401.7140 
2.00 
 
1.00 -255.32468 156.13311 .243 -635.7130 125.0636 
3.00 -160.25824 168.67498 .612 -571.2024 250.6859 
3.00 
 
1.00 -95.06643 125.86569 .732 -401.7140 211.5811 


















Increase in resting during fatigue - between group comparison (both treatments – vehicle 




 Sum of Squares df Mean Square F Sig. 
Between Groups .004 2 .002 .278 .759 
Within Groups .267 39 .007   
Total .271 41    
 
 
1= mdx 2= Utr-/-/mdx  3= con 
Multiple Comparisons  
VAR00048 
Tukey HSD 
(I) VAR00049 (J) VAR00049 
Mean 










2.00 .023208 .035899 .795 -.06425 .11067 
3.00 -.004671 .028940 .986 -.07518 .06583 
2.00 
 
1.00 -.023208 .035899 .795 -.11067 .06425 
3.00 -.027879 .038783 .754 -.12237 .06661 
3.00 
 
1.00 .004671 .028940 .986 -.06583 .07518 



















Time to fatigue - between group comparison (ALLN only) – one way Anova and Tukey 




 Sum of Squares df Mean Square F Sig. 
Between Groups 517910.714 2 258955.357 1.115 .348 
Within Groups 4411421.433 19 232180.075   
Total 4929332.148 21    
1= mdx 2= Utr-/-/mdx   3= con 
Multiple Comparisons  
VAR00059 
Tukey HSD 
(I) VAR00060 (J) VAR00060 
Mean 
Difference (I-J) Std. Error Sig. 








2.00 334.23333 288.91538 .491 -393.9982 1062.4649 
3.00 229.23333 220.66276 .561 -326.9627 785.4294 
2.00 
 
1.00 -334.23333 288.91538 .491 -1062.4649 393.9982 
3.00 -105.00000 323.01721 .944 -919.1876 709.1876 
3.00 
 
1.00 -229.23333 220.66276 .561 -785.4294 326.9627 























Time to fatigue - between group comparison (Vehicle only) – one way Anova and Tukey




 Sum of Squares df Mean Square F Sig. 
Between Groups 91811.025 2 45905.513 1.762 .208 
Within Groups 364782.857 14 26055.918   
Total 456593.882 16    
1= mdx 2= Utr-/-/mdx   3= con 









J) Std. Error Sig. 








2.00 78.00000 111.38932 .767 -213.5371 369.5371 
3.00 -115.14286 86.28179 .400 -340.9665 110.6808 
2.00 
 
1.00 -78.00000 111.38932 .767 -369.5371 213.5371 
3.00 -193.14286 111.38932 .228 -484.6799 98.3942 
3.00 
 
1.00 115.14286 86.28179 .400 -110.6808 340.9665 























Increase in resting during fatigue - between group comparison (ALLN only) – one way 
Anova and Tukey HSD for post hoc analysis 
ANOVA  
VAR00015 
 Sum of Squares df Mean Square F Sig. 
Between Groups .010 2 .005 .603 .556 
Within Groups .170 21 .008   
Total .180 23    
1= mdx 2= Utr-/-/mdx   3= con 









J) Std. Error Sig. 
95% Confidence Interval 




2.00 .04113 .05689 .753 -.1022 .1845 
3.00 -.02820 .04345 .795 -.1377 .0813 
2.00 
 
1.00 -.04113 .05689 .753 -.1845 .1022 
3.00 -.06933 .06360 .530 -.2296 .0910 
3.00 
 
1.00 .02820 .04345 .795 -.0813 .1377 
























Increase in resting during fatigue - between group comparison (Vehicle only) – one way 
Anova and Tukey HSD for post hoc analysis 
ANOVA  
VAR00015 
 Sum of Squares df Mean Square F Sig. 
Between Groups .001 2 .000 .058 .944 
Within Groups .089 15 .006   
Total .089 17    
 
1= mdx 2= Utr-/-/mdx   3= con 









J) Std. Error Sig. 







2.00 .008143 .048195 .984 -.11704 .13333 
3.00 .014000 .041101 .938 -.09276 .12076 
2.00 
 
1.00 -.008143 .048195 .984 -.13333 .11704 
3.00 .005857 .048195 .992 -.11933 .13104 
3.00 
 
1.00 -.014000 .041101 .938 -.12076 .09276 


























 Sum of Squares df Mean Square F Sig. 
Between Groups 40268.720 1 40268.720 3.515 .088 
Within Groups 126004.357 11 11454.942   
Total 166273.077 12    
 
Increase in resting during fatigue – within group comparison (CON) (Vehicle vs. ALLN) 
– One-way Anova 
ANOVA  
VAR00017 
 Sum of Squares df Mean Square F Sig . 
Between Groups .007 1 .007 .817 .385 
Within Groups .092 11 .008   
Total .098 12    
 
 
Time to fatigue – within group comparison (mdx) (Vehicle vs. ALLN) – One-way Anova 
ANOVA  
VAR00019 
 Sum of Squares df Mean Square F Sig. 
Between Groups 258513.839 1 258513.839 1.146 .297 
Within Groups 4512484.933 20 225624.247   
Total 4770998.773 21    
 
 
Increase in resting during fatigue – within group comparison (mdx) (Vehicle vs. ALLN) 
– One-way Anova 
ANOVA  
VAR00021 
 Sum of Squares df Mean Square F Sig. 
Between Groups .000 1 .000 .010 .920 
Within Groups .122 20 .006   









 Sum of Squares df Mean Square F Sig. 
Between Groups 123.857 1 123.857 .006 .943 
Within Groups 111278.500 5 22255.700   
Total 111402.357 6    
 
 





 Sum of Squares df Mean Square F Sig. 
Between Groups .001 1 .001 .164 .702 
Within Groups .045 5 .009   




























Fura-2 ratio resting values 
 
Resting Fura-2 ratio - between groups comparison – One-way ANOVA with Tukey HSD 
for post hoc analysis 
ANOVA  
DedepentV 
 Sum of Squares df Mean Square F Sig. 
Between Groups .009 2 .005 4.399 .016 
Within Groups .073 70 .001   
Total .082 72    
1 = CON 2= mdx 3= Utr-/-/mdx 
Multiple Comparisons  
DedepentV 
Tukey HSD 
(I) Groups (J) Groups Mean 
Difference (I-
J) Std. Error Sig. 
95% Confidence Interval 




2.00 -.030392* .010462 .013 -.05544 -.00534 
3.00 -.018440 .012726 .322 -.04891 .01203 
2.00 
 
1.00 .030392* .010462 .013 .00534 .05544 
3.00 .011951 .009849 .449 -.01163 .03554 
3.00 
 
1.00 .018440 .012726 .322 -.01203 .04891 
2.00 -.011951 .009849 .449 -.03554 .01163 




















Time to 75% of Fura-2 peak clearance 
 








CON - 50Hz vs 120Hz  - paired T-test 
 
























.01254 .00348 -.01073 .00442 -.907 12 .382 
























.03331 .00589 -.01789 .00613 -.999 31 .326 




























Time to 75% of Fura-2 peak clearance 
 
Between groups - 50Hz  - One-way ANOVA with Tukey HSD for post hoc analysis 




 Sum of Squares df Mean Square F Sig. 
Between Groups .018 2 .009 4.461 .016 
Within Groups .102 50 .002   
Total .120 52    
 
1 = mdx 2 = Utr-/-/mdx  3 =  con 
Multiple Comparisons  
VAR00044 
Tukey HSD 
(I) VAR00046 (J) VAR00046 
Mean 
Difference (I-J) Std. Error Sig. 







2.00 -.04129 .01785 .063 -.0844 .0018 
3.00 .01898 .01485 .414 -.0169 .0549 
2.00 
 
1.00 .04129 .01785 .063 -.0018 .0844 
3.00 .06027* .02029 .012 .0113 .1093 
3.00 
 
1.00 -.01898 .01485 .414 -.0549 .0169 
2.00 -.06027* .02029 .012 -.1093 -.0113 


















Time to 75% of Fura-2 peak clearance 
 





 Sum of Squares df Mean Square F Sig. 
Between Groups .011 2 .006 3.460 .039 
Within Groups .082 50 .002   
Total .093 52    
 
1 = mdx 2 = Utr-/-/mdx  3 = con 









J) Std. Error Sig. 
95% Confidence Interval 




2.00 -.02578 .01600 .250 -.0644 .0129 
3.00 .02171 .01331 .242 -.0104 .0539 
2.00 
 
1.00 .02578 .01600 .250 -.0129 .0644 
3.00 .04749* .01819 .031 .0036 .0914 
3.00 
 
1.00 -.02171 .01331 .242 -.0539 .0104 
2.00 -.04749* .01819 .031 -.0914 -.0036 



















 Sum of Squares df Mean Square F Sig. 
Between Groups 749.163 2 374.582 7.823 .001 
Within Groups 3207.922 67 47.879   
Total 3957.086 69    
 
1-way ANOVA with Tukey HSD for post hoc analysis 
1 = mdx 2 = Utr-/-/mdx  3 =  con 
 









J) Std. Error Sig. 
95% Confidence Interval 




2.00 8.17276* 2.12919 .001 3.0693 13.2762 
3.00 -.02504 2.19009 1.000 -5.2744 5.2243 
2.00 
 
1.00 -8.17276* 2.12919 .001 -13.2762 -3.0693 
3.00 -8.19780* 2.66514 .008 -14.5858 -1.8098 
3.00 
 
1.00 .02504 2.19009 1.000 -5.2243 5.2744 
2.00 8.19780* 2.66514 .008 1.8098 14.5858 
*. The mean difference is significant at the 0.05 level. 
 























 Sum of Squares df Mean Square F Sig. 
Between Groups 10733.997 2 5366.998 1.007 .371 
Within Groups 357245.489 67 5332.022   
Total 367979.486 69    
 
1-way ANOVA with Tukey HSD for post hoc analysis 
1 = mdx 2 = Utr-/-/mdx  3 =  con 
 









J) Std. Error Sig. 
95% Confidence Interval 




2.00 29.67774 22.46907 .389 -24.1780 83.5334 
3.00 18.91950 23.11182 .693 -36.4768 74.3158 
2.00 
 
1.00 -29.67774 22.46907 .389 -83.5334 24.1780 
3.00 -10.75824 28.12498 .923 -78.1705 56.6540 
3.00 
 
1.00 -18.91950 23.11182 .693 -74.3158 36.4768 













Peak Fura-2 fluorescence 
 




 Sum of Squares df Mean Square F Sig. 
Between Groups .076 2 .038 1.791 .174 
Within Groups 1.476 70 .021   
Total 1.551 72    
 
1 = mdx 2 = Utr-/-/mdx  3 =  con 









J) Std. Error Sig. 
95% Confidence Interval 




2.00 .04120 .04432 .624 -.0649 .1473 
3.00 .08285 .04561 .172 -.0264 .1921 
2.00 
 
1.00 -.04120 .04432 .624 -.1473 .0649 
3.00 .04165 .05593 .738 -.0923 .1756 
3.00 
 
1.00 -.08285 .04561 .172 -.1921 .0264 




















Peak Fura-2 fluorescence 
 






 Sum of Squares df Mean Square F Sig. 
Between Groups .112 2 .056 .751 .476 
Within Groups 5.216 70 .075   
Total 5.328 72    
 
1 = mdx 2 = Utr-/-/mdx  3 =  con 
Multiple Comparisons  







J) Std. Error Sig. 
95% Confidence Interval 




2.00 .05767 .08332 .769 -.1419 .2572 
3.00 .09793 .08574 .492 -.1074 .3033 
2.00 
 
1.00 -.05767 .08332 .769 -.2572 .1419 
3.00 .04026 .10514 .922 -.2115 .2920 
3.00 
 
1.00 -.09793 .08574 .492 -.3033 .1074 



















Peak Fura-2 fluorescence 
 






 Sum of Squares df Mean Square F Sig. 
Between Groups .167 2 .084 .687 .507 
Within Groups 8.516 70 .122   
Total 8.683 72    
 
1 = mdx 2 = Utr-/-/mdx  3 =  con 








J) Std. Error Sig. 
95% Confidence Interval 




2.00 .09297 .10646 .659 -.1620 .3479 
3.00 .10511 .10956 .605 -.1572 .3674 
2.00 
 
1.00 -.09297 .10646 .659 -.3479 .1620 
3.00 .01214 .13434 .996 -.3095 .3338 
3.00 
 
1.00 -.10511 .10956 .605 -.3674 .1572 



















Peak Fura-2 fluorescence 
 






 Sum of Squares df Mean Square F Sig. 
Between Groups .207 2 .104 .676 .512 
Within Groups 10.572 69 .153   
Total 10.779 71    
 
1 = mdx 2 = Utr-/-/mdx  3 =  con 
Multiple Comparisons  







J) Std. Error Sig. 
95% Confidence Interval 




2.00 .12758 .11979 .539 -.1594 .4145 
3.00 .08627 .12325 .764 -.2090 .3815 
2.00 
 
1.00 -.12758 .11979 .539 -.4145 .1594 
3.00 -.04131 .15077 .959 -.4024 .3198 
3.00 
 
1.00 -.08627 .12325 .764 -.3815 .2090 



















Peak Fura-2 fluorescence 
 






 Sum of Squares df Mean Square F Sig. 
Between Groups .176 2 .088 .423 .657 
Within Groups 13.925 67 .208   
Total 14.101 69    
 
1 = mdx 2 = Utr-/-/mdx  3 =  con 
Multiple Comparisons  







J) Std. Error Sig. 
95% Confidence Interval 




2.00 .12902 .14028 .630 -.2072 .4653 
3.00 .03332 .14429 .971 -.3125 .3792 
2.00 
 
1.00 -.12902 .14028 .630 -.4653 .2072 
3.00 -.09570 .17559 .849 -.5166 .3252 
3.00 
 
1.00 -.03332 .14429 .971 -.3792 .3125 



















Peak Fura-2 fluorescence 
 







 Sum of Squares df Mean Square F Sig. 
Between Groups .144 2 .072 .325 .724 
Within Groups 14.654 66 .222   
Total 14.798 68    
 
1 = mdx 2 = Utr-/-/mdx  3 =  con 








J) Std. Error Sig. 
95% Confidence Interval 




2.00 .11571 .14542 .707 -.2329 .4644 
3.00 .01023 .14955 .997 -.3483 .3688 
2.00 
 
1.00 -.11571 .14542 .707 -.4644 .2329 
3.00 -.10548 .18149 .831 -.5406 .3297 
3.00 
 
1.00 -.01023 .14955 .997 -.3688 .3483 



















Peak Fura-2 fluorescence 
 






 Sum of Squares df Mean Square F Sig. 
Between Groups .191 2 .096 .415 .662 
Within Groups 14.980 65 .230   
Total 15.171 67    
 
1 = mdx 2 = Utr-/-/mdx  3 =  con 









J) Std. Error Sig. 
95% Confidence Interval 




2.00 .11177 .14860 .733 -.2447 .4682 
3.00 -.04767 .15280 .948 -.4142 .3188 
2.00 
 
1.00 -.11177 .14860 .733 -.4682 .2447 
3.00 -.15944 .18490 .666 -.6029 .2841 
3.00 
 
1.00 .04767 .15280 .948 -.3188 .4142 


















Pre vs. Post peak values 
mdx (ALLN) – pre vs. post-fatigue comparison – paired t-test 
Paired Samples Statistics  
 Mean N Std. Deviation Std. Error Mean 
Pair 1 Pre-10hz .6889 15 .12962 .03347 
post-10Hz .6359 15 .16461 .04250 
Pair 2 Pre-30Hz 1.0115 15 .25397 .06558 
post-30Hz .9019 15 .32089 .08285 
Pair 3 Pre-50Hz 1.1955 15 .33623 .08681 
post-50Hz 1.0413 15 .41894 .10817 
Pair 4 Pre-70Hz 1.3106 15 .38545 .09952 
post-70Hz 1.1564 15 .45052 .11632 
Pair 5 Pre-100Hz 1.3849 15 .43515 .11236 
post-100Hz 1.2008 15 .52459 .13545 
Pair 6 Pre-120Hz 1.4275 15 .45089 .11642 
post-120Hz 1.2622 15 .53501 .13814 
Pair 7 Pre-150Hz 1.4341 15 .45323 .11702 
post-150Hz 1.2878 15 .54214 .13998 













95% Confidence Interval 



















































































Pre vs. Post peak values  
mdx (Vehicle) – pre vs. post-fatigue comparison – paired t-test 
Paired Samples Statistics  
 
Mean N Std. Deviation 
Std. Error 
Mean 
Pair 1 Pre-10hz .7215 15 .16015 .04135 
post-10Hz .6130 15 .14876 .03841 
Pair 2 Pre-30Hz 1.0641 15 .32138 .08298 
post-30Hz .8985 15 .34039 .08789 
Pair 3 Pre-50Hz 1.2664 15 .42505 .10975 
post-50Hz 1.0641 15 .46232 .11937 
Pair 4 Pre-70Hz 1.3887 15 .48520 .12528 
post-70Hz 1.1495 15 .53178 .13730 
Pair 5 Pre-100Hz 1.4993 15 .54517 .14076 
post-100Hz 1.2161 15 .61062 .15766 
Pair 6 Pre-120Hz 1.5206 15 .55415 .14308 
post-120Hz 1.2116 15 .59881 .15461 
Pair 7 Pre-150Hz 1.5125 15 .53551 .13827 
post-150Hz 1.2151 15 .61154 .15790 





















































Pre vs. Post peak values 
con (Vehicle) – pre vs. post-fatigue comparison – paired t-test 
Paired Samples Statistics  
 
Mean N Std. Deviation 
Std. Error 
Mean 
Pair 1 Pre-10hz .5864 5 .14814 .06625 
post-10Hz .6324 5 .16871 .07545 
Pair 2 Pre-30Hz .8268 5 .25881 .11574 
post-30Hz .9462 5 .35236 .15758 
Pair 3 Pre-50Hz .9750 5 .33691 .15067 
post-50Hz 1.1382 5 .45356 .20284 
Pair 4 Pre-70Hz 1.0764 5 .37798 .16904 
post-70Hz 1.2890 5 .56192 .25130 
Pair 5 Pre-100Hz 1.2114 5 .47874 .21410 
post-100Hz 1.4220 5 .63618 .28451 
Pair 6 Pre-120Hz 1.2718 5 .51146 .22873 
post-120Hz 1.4742 5 .66290 .29646 
Pair 7 Pre-150Hz 1.3864 5 .57331 .25639 
post-150Hz 1.5402 5 .69970 .31291 






















































Pre vs. Post peak values  
con (ALLN) – pre vs. post-fatigue comparison – paired t-test 
Paired Samples Statistics  
 
Mean N Std. Deviation 
Std. Error 
Mean 
Pair 1 Pre-10hz .7014 5 .11674 .05221 
post-10Hz .7322 5 .09319 .04168 
Pair 2 Pre-30Hz 1.2878 5 .30151 .13484 
post-30Hz 1.2580 5 .22051 .09861 
Pair 3 Pre-50Hz 1.2686 5 .35983 .16092 
post-50Hz 1.2600 5 .28664 .12819 
Pair 4 Pre-70Hz 1.5224 5 .43858 .19614 
post-70Hz 1.4966 5 .37642 .16834 
Pair 5 Pre-100Hz 1.7310 5 .54063 .24178 
post-100Hz 1.6766 5 .47786 .21371 
Pair 6 Pre-120Hz 1.8158 5 .60779 .27181 
post-120Hz 1.7752 5 .57654 .25784 
Pair 7 Pre-150Hz 1.9724 5 .61917 .27690 
post-150Hz 1.5648 5 .77900 .34838 






















































Pre vs. Post peak values  
Utr-/-/mdx (Vehicle) – pre vs. post-fatigue comparison – paired t-test 
Paired Samples Statistics  
 
Mean N Std. Deviation 
Std. Error 
Mean 
Pair 1 Pre-10hz .8225 2 .09263 .06550 
post-10Hz .5540 2 .27153 .19200 
Pair 2 Pre-30Hz 1.2265 2 .09263 .06550 
post-30Hz .7055 2 .46598 .32950 
Pair 3 Pre-50Hz 1.4550 2 .09051 .06400 
post-50Hz .7770 2 .54589 .38600 
Pair 4 Pre-70Hz 1.5915 2 .09970 .07050 
post-70Hz .7970 2 .56710 .40100 
Pair 5 Pre-100Hz 1.7240 2 .11031 .07800 
post-100Hz .7600 2 .49497 .35000 
Pair 6 Pre-120Hz 1.6775 2 .00212 .00150 
post-120Hz .7665 2 .49992 .35350 
Pair 7 Pre-150Hz 1.5495 2 .02758 .01950 
post-150Hz .7880 2 .53033 .37500 






















































Pre vs. Post peak values 
Utr-/-/mdx (ALLN) – pre vs. post-fatigue comparison – paired t-test 
Paired Samples Statistics 
 
Mean N Std. Deviation 
Std. Error 
Mean 
Pair 1 Pre-10hz .7710 2 .01980 .01400 
post-10Hz .6235 2 .36982 .26150 
Pair 2 Pre-30Hz 1.1475 2 .01909 .01350 
post-30Hz .9030 2 .74529 .52700 
Pair 3 Pre-50Hz 1.3560 2 .04950 .03500 
post-50Hz 1.0570 2 .94187 .66600 
Pair 4 Pre-70Hz 1.4830 2 .05374 .03800 
post-70Hz 1.1480 2 1.06349 .75200 
Pair 5 Pre-100Hz 1.6255 2 .02899 .02050 
post-100Hz 1.1705 2 1.07551 .76050 
Pair 6 Pre-120Hz 1.6765 2 .00071 .00050 
post-120Hz 1.0645 2 .92136 .65150 
Pair 7 Pre-150Hz 1.6280 2 .13859 .09800 
post-150Hz .6525 2 .33870 .23950 
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